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Abstract
Few proteins have come under such intense scrutiny as superoxide dismutase-1 (SOD1). For
almost a century, scientists have dissected its form, function and then later its malfunction in
the neurodegenerative disease amyotrophic lateral sclerosis (ALS). We now know SOD1 is a
zinc and copper metalloenzyme that clears superoxide as part of our antioxidant defence and
respiratory regulation systems. The possibility of reduced structural integrity was suggested by
the first crystal structures of human SOD1 even before deleterious mutations in the sod1 gene
were linked to the ALS. This concept evolved in the intervening years as an impressive array of
biophysical studies examined the characteristics of mutant SOD1 in great detail. We now rec-
ognise how ALS-related mutations perturb the SOD1 maturation processes, reduce its ability
to fold and reduce its thermal stability and half-life. Mutant SOD1 is therefore predisposed to
monomerisation, non-canonical self-interactions, the formation of small misfolded oligomers
and ultimately accumulation in the tell-tale insoluble inclusions found within the neurons of
ALS patients. We have also seen that several post-translational modifications could push wild-
type SOD1 down this toxic pathway. Recently we have come to view ALS as a prion-like
disease where both the symptoms, and indeed SOD1 misfolding itself, are transmitted to
neighbouring cells. This raises the possibility of intervention after the initial disease presenta-
tion. Several small-molecule and biologic-based strategies have been devised which directly
target the SOD1 molecule to change the behaviour thought to be responsible for ALS.
Here we provide a comprehensive review of the many biophysical advances that sculpted
our view of SOD1 biology and the recent work that aims to apply this knowledge for thera-
peutic outcomes in ALS.
Introduction: the four ages of SOD1 discovery
There are roughly 500 new scientific publications relating to superoxide dismutase-1 (SOD1)
every year. The deluge of information over the last few years is however relatively small in
comparison with totality of knowledge accrued over the 80 years in which SOD1 has been
a subject of scientific investigation. This level of interest reflects its prevalence and importance
in our physiological processes, the relative ease with which one can work with SOD1 and its
limitless capacity to retain enigma. The story of SOD1 recapitulates that of the golden age in
Life Sciences which occurred over the last century. As new technologies have become available,
SOD1 has proved an interesting and amenable test-case. Biophysics has been fruitful in pro-
viding answers to questions in SOD1 biology. In this section, we give a history of the discovery
of SOD1, which can be divided into four distinct periods, and then describe how biophysics
has shaped our view of SOD1 in relation to the neurodegenerative disease amyotrophic lateral
sclerosis (ALS).
A source of copper in blood
The first age of SOD1 discovery began two centuries ago with the work of chemists, such as
Christian Friedrich Bucholz, who found copper to be a constituent of plant and animal tissue.
Subsequently, in the latter half of the 19th century, came the discovery of zinc in biological
materials. The copper and zinc under investigation here comprised several different sources
but a portion of it was present as co-factors for what would become known as haemocuprein
and later SOD1.
In the late 1920s and 30s, a copper source was identified in the blood that could be freed
from its organic component with the addition of hydrochloric or trichloroacetic acids but
could not be removed by dialysis except at low pH (Warburg and Krebs, 1927; Locke et al.,
1932). Eisler et al. (1936) found that all of the copper in blood serum was bound to protein.
In seminal papers, Thaddeus Mann and David Keilin described the purification of a ‘distinctly
blue’ protein, which they named haemocuprein, from cow, sheep and horse blood together
with the first of many methods for its crystallisation (Mann and Keilin, 1938a, 1938b).
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Calculation of its copper content indicated that one 35 kDa SOD1
molecule contained two copper atoms. Subsequent experiments
on erythrocuprein purified from human blood refined the molec-
ular mass to 33 kDa and indicated it possessed high thermal
stability (Markowitz et al., 1959). Cerebrocuprein and hepatocu-
prein isolated from brain and liver, respectively, were found to
be identical to the protein isolated from blood but no function
could be ascribed (Mann and Keilin, 1938b; Porter et al., 1957;
Carrico and Deutsch, 1969). Variable copper metalation, depen-
dent on source, and the ability to reversibly bind copper led to
the hypothesis that erythrocuprein acts as copper storage sink
rather than an enzyme (Mohamed and Greenberg, 1954).
Concurrently with the initial characterisation of erythrocu-
prein, Linus Pauling’s investigation of the implications of quan-
tum mechanics on covalent bonding had predicted the existence
of three-electron bonds (Pauling, 1931). This led Edward
Neuman to the discovery of the potassium superoxide state of
the substance then known as potassium tetroxide. Superoxide
was found to be paramagnetic with one unpaired electron
(Neuman, 1934). Superoxide anion is the product of univalent
reduction of dioxygen. Its primary reaction in aqueous solvents
is the spontaneous, second-order dismutation to hydrogen perox-
ide and water (McClune and Fee, 1976). Understanding of the
biological implications of superoxide generation began with bio-
chemical characterisation of xanthine oxidase. Cytochrome c
was found to be reduced by xanthine oxidase in the presence of
its substrates. The rate of this reaction was increased under aero-
bic conditions and hypothesised to be mediated by superoxide
(Horecker and Heppel, 1949; Rabani and Stein, 1962).
Conversely, the reaction of xanthine oxidase with its substrate
was shown to catalyse a chain reaction of aerobic auto-oxidation
of sulphite via superoxide free radicals (Fridovich and Handler,
1958, 1961). Their observations of superoxide led Joe McCord
and Irwin Fridovich to propose a scheme for the dismutation
reaction (Fig. 1a) and write, ‘once generated, this radical could
be very damaging to the components of the cell by virtue of its
high reactivity’ (McCord and Fridovich, 1968).
A cupro-enzyme with dismutase activity
Discovery of erythrocuprein’s activity, and with it the beginning
of the second age of SOD1 discovery, was a combination of
many years of the rigorous biochemistry described above, and
luck. McCord and Fridovich (1968) found that cytochrome
c reduction by xanthene oxidase activity could be inhibited by car-
bonic anhydrase and myoglobin. On the verge of publication, the
authors found that inhibition was due to an unknown impurity
in both carbonic anhydrase and myoglobin preparations. From
that position, the SOD activity of the impurity, erythrocuprein,
was proven and the centrality of its copper cofactor in the dismu-
tation reaction (McCord and Fridovich, 1969; Klug et al., 1972)
(Fig. 1b). In parallel, SOD1 was discovered to bind zinc in stoichio-
metric amounts to copper (Carrico and Deutsch, 1970).
Why does nature use superoxide dismutases?
‘There is a bizarre enzymatic activity universally present in respiring cells.
The substrate is an unstable free radical that can be present only in minus-
cule amounts at any instant, and the reaction catalyzed proceeds at a rapid
rate even in the absence of the enzyme’ (Fridovich, 1975).
When a SOD was first isolated from Escherichia coli, it was found
to be pink and contained manganese rather than copper and zinc
(Keele et al., 1970). Iron SODs are related to these manganese
SODs and another evolutionarily distinct form are the nickel
SODs (Smith and Doolittle, 1992; Youn et al., 1996). Copper/
zinc superoxide dismutases (CuZnSOD) are found in the cyto-
plasm, intermembrane space of mitochondria, peroxisomes,
nucleus, and the extracellular space of eukaryotes, and the peri-
plasm of some prokaryotes. Manganese SODs are found in
eukaryotic mitochondrial matrices as well as the prokaryotic cyto-
plasm, as are iron SODs. Nickel SODs are also largely prokaryotic.
In almost every biological space, there is a SOD enzyme that oper-
ates within it. When oxygen is used in metabolism, SOD activity
tends to be high and when organisms are exposed to oxygen, but
it is not used in metabolism, SOD activity is low or inducible
(Tally et al., 1977). The exception which proves this rule is the
obligate anaerobes which have very low or non-existent SOD
activity (McCord et al., 1971). Thus, enzymatic SOD activity is
primarily a response to the presence or use of oxygen
(Gerschman et al., 1954) but may have evolved prior to Earth’s
great oxidation event, concomitantly with oxygenic photosynthe-
sis. Please see excellent reviews of SOD evolution (Case, 2017) and
structure (Perry et al., 2010).
Superoxide is produced by many eukaryotic cellular processes
and in different locations. The respiratory electron transport chain
(ETC) found in the mitochondrial inner membrane provides the
proton-motive force for ATP generation but contains at least 11
sites where electrons can be lost to the surrounding oxygen-rich
environment (Wong et al., 2017). Here superoxide is a
Janus-faced component of the oxidative stress-redox signalling
equilibrium; it is potentially damaging to any biological molecule,
including mitochondrial DNA, while it also acts as a signal-
transducer modulating respiration in a negative freed-back loop.
Electrons can be shed by the mitochondrial ETC into the matrix
where it forms superoxide and is detoxified by manganese SODs.
Conversely, the ETC complex III (cytochrome bc1 complex) can
shed electrons from its Qo site into the intermembrane space
(Han et al., 2001; Bleier and Dröse, 2013) where it is likely to
undergo dismutation catalysed by SOD1. Xanthene oxidase,
inducible nitric oxide synthase and NADPH-oxidase enzymes
all produce superoxide in various cellular compartments, and as
a result, SOD1 is usually found in their environs. An example is
peroxisomes, which are voracious oxygen consumers and prolific
reactive oxygen species producers, and as a result, they too house
SOD1 (Fransen et al., 2012).
SOD1 structure discovery
Metal binding and disulphide bonding
With a function attributed to the previously mysterious erythro-
cuprein (McCord and Fridovich, 1969), means of purification
and enzymatic assay well described, the third age of SOD1
Fig. 1. Dismutation of superoxide anion. (a) The spontaneous dismutation of super-
oxide to oxygen and hydrogen peroxide (McCord and Fridovich, 1968). (b) Two
steps in the SOD1 catalysed dismutation of superoxide which cyclically reduces
then oxidises the copper centre (Klug et al., 1972).
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discovery began in earnest with biochemical and biophysical
characterisation. Human and bovine SOD1 were each found to
be composed of two sub-units of 16 kDa with strong interactions.
This indicated that SOD1 is dimeric with high dimer affinity
(Keele et al., 1971; Hartz and Deutsch, 1972). Keele et al.
(1971) found that disulphide reduction along with dodecyl sul-
phate denaturation was necessary to form monomeric SOD1.
They concluded that a disulphide bond linked the SOD1 subunits.
This was subsequently disproved by Hartz and Deutsch (1972),
but these experiments form the first understanding of the role
of metalation and disulphide state in the stability of SOD1. A
SOD1 intra-subunit disulphide was later confirmed in the wheat
CuZnSOD orthologue and a similar bond was shown to link
bovine SOD1 Cys55 and Cys144 (Cys57 and Cys146 human num-
bering) (Beauchamp and Fridovich, 1973; Abernethy et al., 1974).
Analysing circular dichroism (CD) spectra from metalated, metal-
apo and disulphide-reduced bovine SOD1, Wood et al. (1971)
predicted the proximity of copper and zinc in the SOD1 structure
and indicated the presence of one tryptophan per subunit. From
electron paramagnetic resonance studies of SOD1 with the spec-
troscopically silent zinc replaced by cobalt, Rotilio et al. (1974)
again demonstrated the proximity of the metal sites but also
showed the zinc ion is not solvent exposed.
Wood et al. (1971) showed SOD1 has a β-sheet rich fold that is
not significantly perturbed by metal removal. However, metal-free
SOD1 is more susceptible to chaotrope-induced unfolding than
the metalated form. They also ascertained that the disulphide
bond has an impact on SOD1 tertiary structure. Forman and
Fridovich (1973) found similar characteristics using enzyme activ-
ity and resistance to proteolysis as a measure of stability. With this
approach, they gleaned that the zinc ion has a greater impact on
stability than activity. The paradigm established here of metal loss
and disulphide reduction contributing to SOD1 monomerisation
and instability would become increasingly important following
linkage with ALS two decades later.
The first crystallographic bovine SOD1 structure
The pursuit of a crystallographic structure of SOD1 ensued shortly
after SOD catalytic activity was demonstrated. For the first decade,
this work was dominated by Jane and David Richardson at Duke
University which yielded the structure of bovine SOD1 and invalu-
able insight on protein structure as a whole.
X-ray diffraction from SOD1 was first observed from crystals
grown in phosphate buffer and 2-methyl-2,4-pentanediol which
diffracted to 2 Å resolution using the precession method
(Richardson et al., 1972). With the revolution in synchrotron
radiation crystallography still a decade away, data from multiple
crystals were collected using a Picker 4-circle x-ray diffractometer
based on a sealed tube. The structure was solved at 5.5 Å resolu-
tion by multiple isomorphous replacements using a combination
of heavy atom derivatives soaked for up to 3 months with mercury
substituted in the SOD1 zinc site (Thomas et al., 1974). The
authors noted a 15 Å diameter hollow passing through the centre
of each monomer which they attributed to adoption of an antipar-
allel β-cylinder structure (Fig. 2a). A year later brought a refine-
ment of this structure to 3 Å resolution and with it tracing the
back-bone, assignment of Cα positions and positioning of some
side chains (PDB: 1SOD) (Richardson et al., 1975a, 1975b).
This joined the list of a dozen or so high-resolution structures
at the time that included myoglobin, haemoglobin, lysozyme,
ribonucleases A and S, carboxypeptidase, cytochrome c, chymo-
trypsin and immunoglobins.
The above research indicated that the SOD1 monomer pos-
sesses an eight stranded anti-parallel β-barrel (Fig. 2b), with the
hydrophobic inner core, which constitutes roughly half of the
protein backbone. The remainder of the structure is found in
two loops (Fig. 2c). The ‘external loop’ (loop VII, amino acids
122–144 in the human enzyme and now commonly called the
electrostatic loop), which was visible in the 5.5 Å resolution
map, had unknown functional significance. A second loop
(loop IV, amino acids 49–83, named the zinc loop) provides
three coordinating ligands to the zinc ion and is held against
the β-barrel by a disulphide bond but also forms part of the
dimer interface along with the C-terminus and part of the
β-barrel surface. Copper and zinc coordinating amino acids
could be defined and the copper site geometry was categorised
as distorted square planar with solvent accessibility to the copper
ion (Fig. 3). The proposition that both subunits in the SOD1
dimer are conformationally identical was raised along with inter-
face hydrogen bonding (Fig. 3).
Fig. 2. The β-strand, loop and barrel structure of human SOD1. (a) β-barrel component of human SOD1 with approximately 15 Å diameter as described for bovine
SOD1 (Thomas et al., 1974). (b) Greek-key assembly of SOD1 β-strands showing loops which facilitate position swap of β-strands 4 and 6 in orange. (c) Arrangement
of human SOD1 secondary structures within the β-barrel with residues involved in copper and zinc binding highlighted blue and grey respectively.
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Immunoglobin-like fold
Of particular interest was the similarity between the SOD1
β-barrel structure and other immunoglobulin domains despite
sequence and functional diversity. Where SOD1 had disulphide,
zinc binding and external loops connecting β-strands, hyper-
variable loops could be found in immunoglobulin structures
(Richardson et al., 1975a). This led to the deduction of a nomen-
clature for β-sheet structures, the ‘Greek key’ sobriquet for the
β-barrel arrangement typical of SOD1-like proteins, and a series
of protein domain structure rules. The latter included conserva-
tion of β-structure over sequence, conservation of disulphide con-
nectivity and the potential for insertions and deletions to occur in
loops but not within secondary structure elements thus engineer-
ing functionality without detriment to stability (Richardson et al.,
1976; Richardson, 1977). It was also noted that similar domains
may use different interaction surfaces for oligomerisation, a fact
now easily observed by comparison of prokaryotic and eukaryotic
CuZnSOD dimerisation (Bourne et al., 1996).
Structure refinement and a catalytic mechanism
Working in the Richardsons’ laboratory, Elizabeth Getzoff and
John Tainer were subsequently able to extend the limit of usable
data to 2 Å and improve the bovine SOD1 model (PDB: 2SOD)
with the stereochemistry and non-crystallographic symmetry
restrained with Hendrickson–Konnert least-squares refinement
(Tainer et al., 1982). This allowed for determination of all non-
hydrogen atom positions, placement of a single water molecule
3.2 Å from the copper ion and detailed assessment of hydrogen
bonding interactions that hold the β-barrel and loops in place.
Following further refinement and charge analysis, it became
clear that loops IV and VII create both the active site and the elec-
trostatic forces in and beyond the active site channel that speed
diffusion of superoxide towards the positively charged copper,
zinc and Arg141 (human Arg143) in the correct orientation to
maximise productive interactions (Getzoff et al., 1983). In the
active site, superoxide displaces the copper bound water and
hydrogen bonds with Arg141 side-chain guanidinium. The
unpaired superoxide electron reduces copper (II) and oxygen is
released. The bond between copper and His61 (human His63)
is broken and the histidine is protonated after which it hydrogen
bonds with a second superoxide anion. Arg141 again hydrogen
bonds with the substrate. Addition of another proton and bond
rearrangement creates hydrogen peroxide and oxidises copper
(I) (Tainer et al., 1983). The structure of the fully reduced Cu
(I) enzyme showing complete breakage of the Cu-His61 bond
came two decades later at 1.15 Å resolution using a powerful syn-
chrotron beam and cryogenically maintained crystals (Hough and
Hasnain, 2003).
Recombinant human SOD1 crystallography
Taking advantage of advances in recombinant DNA technology
throughout the 1970s, Getzoff and Tainer embarked on the bio-
physical characterisation of human SOD1. Expressed in
Saccharomyces cerevisiae and crystallised with ammonium sul-
phate and poly-ethylene glycol precipitants, recombinant wild-
type human SOD1 was found to form a variety of crystals
which diffracted to at least 2.8 Å resolution on a rotating anode
x-ray generator setup. Seeding could again be used to stimulate
growth and wild-type crystals were used to grow a free sulphydryl
knock-out, thermostable mutant (Cys6Ala/Cys111Ser) following
mutagenesis of the wild-type expression plasmid (Parge et al.,
1986). It was later shown that the removal of these free cysteines
promotes refolding after thermal denaturation (Hallewell et al.,
1991). This work culminated in the crystal structures of recombi-
nant wild-type and thermal-stable human SOD1 (Parge et al.,
1992). Diffraction data were now collected using synchrotron
radiation on film at the Stanford Synchrotron Radiation
Laboratory or on a Xentronics multi-wire proportional counting
area detector; two developments that would revolutionise protein
crystallography. Structural work continued from this point with
increasing crystallographic resolution allowing ever greater detail
to be revealed (Strange et al., 2006) and nuclear magnetic reso-
nance spectroscopy accessing solution states of SOD1 important
in its journey from polypeptide to active protein (Banci et al.,
1998, 2002, 2006). In our laboratory, we routinely produce crystal
structures of SOD1 in a high-throughput fashion. From initial
Fig. 3. Human SOD1 metal binding and dimerisation regions.
Upper panel – Copper and zinc coordinating (purple and light
blue respectively) sites are linked by His63 (orange). The copper
ion (blue) can be found solvent exposed at two positions depen-
dent on oxidation state while the zinc ion (grey) is internalised.
Lower panel – Hydrogen bonding (orange) at the SOD1 dimer
interface is mediated by backbone interactions of Ile151 with
Gly51 and Gly114.
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exposure of a crystal to x-rays through to seeing a 3D model of
SOD1 now takes only hours rather than years of painstaking
data collection, data reduction and model building. The combina-
tion of all of this work has given us an exquisitely detailed picture
of SOD1 structure.
Amyotrophic lateral sclerosis
ALS is a neurodegenerative disease historically stated as only
affecting the upper and lower motor neurons. Neuron death
leads to a progressive inability to control the musculature and ulti-
mately death usually within 5 years. We now understand that ALS
is a motor system disorder affecting neurons and their support
cells and forms a spectrum of clinical characteristics with fronto-
temporal lobar degeneration. Schizophrenia and cognitive impair-
ment are also associated with ALS; however, this is rare for
SOD1-related ALS. Following the first characterisation by
Jean–Martin Charcot in 1869, conjecture on the aetiology of ALS
varied between sporadic and familial (Kurland and Mulder, 1955).
SOD1 and familial ALS
The existence of SOD1 polymorphisms, prevalent within a spe-
cific geographical location and inherited from one generation to
the next, that could change the physico-chemical properties of
the enzyme was understood long before linkage with ALS was
proven (Brewer, 1967; Beckman, 1973; Lepock et al., 1990;
Banci et al., 1991). We now know that a portion of ALS incidence,
roughly 20%, is attributed to inheritable genetic factors, termed
familial ALS (fALS). A concerted effort to discover a chromo-
somal location associated with ALS came to fruition in 1991
with the discovery of the 21q22.1 locus (Siddique et al., 1991).
In 1993, the focus of SOD1 structure-function research shifted
considerably with the knowledge that 11 amino acid substitutions
in the SOD1 primary sequence were causative for ALS (Rosen
et al., 1993). In the following years, many new ALS-related muta-
tions were discovered including the Asp90Ala identity of the poly-
morphism described by Beckman (1973). In the last decade and a
half, SOD1 has been joined by a disparate group of genes which
have varying modes of inheritance and degrees of ALS pene-
trance. Thus, ALS is a genetically heterogeneous disease. The
year 1993 marked the beginning of the fourth age of SOD1.
Here biophysics would play a fundamental role in our under-
standing of the transformation which turns this normally cyto-
protective enzyme into a neurotoxin.
Biophysical experiments establish the nature of mutant SOD1
Prior to linkage with ALS, Parge et al. (1986) conjectured on the
possibility that β-barrel and dimer interface mutations would
affect SOD1 stability. Months after linkage with SOD1, a working
hypothesis for toxicity was devised by mapping ALS mutations on
the crystal structure of wild-type SOD1. Deng et al. (1993) then
proposed that mutations to amino acids and conformations con-
served in human, yeast and bovine SOD1 structures would desta-
bilise β-barrel, dimer interface and loops. This hypothesis later
became known as frame-work destabilisation (DiDonato et al.,
2003). Over the coming years, SOD1 cytoplasmic inclusions
were found in the motor neurons and associated cells of post-
mortem mutant SOD1 transgenic mice and human ALS patient
tissues (Kato et al., 1996; Shibata et al., 1996a; Bruijn et al.,
1997, 1998). These observations were linked to framework desta-
bilisation by in vitro biophysics experimentation which character-
ised SOD1 thermal instability (Rodriguez et al., 2002; Tiwari and
Hayward, 2005), unfolding propensity (Cardoso et al., 2002;
Lindberg et al., 2002; DiDonato et al., 2003), dimer destabilisation
(Hough et al., 2004) and formation of high molecular mass solu-
ble and insoluble structures (DiDonato et al., 2003; Elam et al.,
2003a; Ray et al., 2004). A consistent theme is the effect of
SOD1 disulphide reduction and the inability to correctly bind
copper and zinc on toxic properties. The structure of metal-
deficient SOD1 shows loop disorder and exposure of the
β-barrel (Strange et al., 2003). In vivo, metal-free, disulphide-
reduced SOD1 is over-represented within SOD1 aggregates indi-
cating a defective post-transitional modification (PTM) pathway
(Jonsson et al., 2006a; Karch et al., 2009; Bourassa et al., 2014).
This brings the story of the pathogenesis of SOD1-reated ALS
back to the first experiments on the newly named SOD1 in the
1970s which showed that the presence of metal cofactors and
the intra-subunit disulphide bond were prerequisites for stability
and activity.
The pathogenesis of SOD1-related ALS
SOD1 mutations
There are more than 180 SOD1 polymorphisms associated with
ALS, the majority of which are collated in the ALSoD database
(Abel et al., 2012). Most are single amino acid substitutions, but
truncations and frame-shift mutations that lead to truncations
can also be found (Fig. 4a). The most common SOD1 polymor-
phisms are Ala4Val (Deng et al., 1993), predominantly found in
North America, and Asp90Ala (Andersen et al., 1995) which is
found in 5% of the Scandinavian population (Andersen et al.,
1996). These two polymorphisms reflect the diversity of SOD1
ALS mutations. They are found in different exons in the SOD1
gene (1 and 4, respectively) which code for amino acids with dif-
ferent properties in different parts of the SOD1 protein with dif-
ferent secondary structure. Ala4Val causes ALS with early onset
and very short duration (Rosen et al., 1994) whereas Asp90Ala
leads to long survival times post presentation (Andersen et al.,
1996).
Much effort relating genotype, molecular characteristics and
disease phenotype has yielded proposed relationships between
SOD1 thermal stability, half-life, aggregation, Km for hydrogen
peroxide, hydrogen bond stability and free energy of wild-type/
mutant heterodimerisation with disease course (Yim et al.,
1997; Sato et al., 2005, 2005; Wang et al., 2008; Prudencio
et al., 2009; Shi et al., 2016). However, the small numbers of peo-
ple which are known to have carried most SOD1 polymorphisms,
which in some cases may be as low as one individual, and the
wide distribution of longevities following the onset of symptoms
significantly hamper the power of these investigations. Other pre-
disposition genes, epigenetic and environmental factors are addi-
tionally all likely to contribute to the phenotype which eventually
leads to symptom onset further complicating this task of unpick-
ing causality in SOD1 ALS.
SOD1-ALS inheritance and penetrance
The majority of SOD1 mutations cause ALS in an autosomal
dominantly inherited fashion. In the heterozygous state,
Ala4Val SOD1 phenotypic penetrance is high. At age 70, 91%
of Ala4Val allele-positive individuals will have developed ALS
(Cudkowicz et al., 1997) but examples do exist of Ala4Val carriers
who remain symptom free (Weiss et al., 2006). By contrast,
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Asp90Ala SOD1 generally results in recessively inherited ALS but
has also been described as dominantly inherited with reduced
penetrance in genetically distinct families (Andersen et al.,
1995; Robberecht et al., 1996). There are several other examples
of ALS mutant SOD1 homozygosity including a 13-year-old
who had two copies of the Asn86Ser allele and died only 3.5
months after presentation. Heterozygotes with the same mutation
have been noted to be asymptomatic or present with typical
mutant SOD1 phenotype (Hayward et al., 1998; Millecamps
et al., 2010). Individuals have also been found homozygous for
a Leu126Ser substitution and a ΔGly27/Pro28 exon 2 splicing-site
variant (Kato et al., 2001a; Zinman et al., 2009). A further exam-
ple describes three compound heterozygous Asp90Ala/Asp96Asn
individuals who presented with early-onset ALS but very long dis-
ease duration (Hand et al., 2001). These cases are indicative that a
necessary load of toxic SOD1 species must be met before cell
death ensues. As ever though SOD1 provides an enigmatic outlier;
a homozygous Leu84Phe 48-year-old individual remained asymp-
tomatic while an unrelated heterozygous individual presented
with ALS at age 45 (Boukaftane et al., 1998).
The Ile113Thr substitution is one of the most common ALS
SOD1 mutations but the resulting phenotype can appear as spora-
dic ALS due to reduced penetrance (Rosen et al., 1993; Suthers
et al., 1994). This high phenotypic variability also includes vari-
able disease onset and duration (Orrell et al., 1999; Lopate
et al., 2010). These characteristics are in stark contrast to
Ala4Val SOD-related ALS despite the proximity of the two muta-
tions; Ala4 and Ile113 side-chains are separated by only 3.7 Å
when the protein is folded and mature. Other mutations have
been noted to yield ALS with incomplete penetrance including
Gly61Arg (Conforti et al., 2011), and Leu67Pro (del Grande
et al., 2011) however, in the absence of detailed immunohisto-
chemistry, it is difficult to ascertain if these are truly
ALS-causing SOD1 mutations or harmless polymorphisms
co-incident with sporadic or low penetrance non-SOD1 fALS as
has been noted for Asp90Ala and Glu100Lys families (Felbecker
et al., 2010). Indeed, SOD1 polymorphisms Ser25Thr,
Ser25Asn, Ser34Ile, His46Tyr, Glu49Val, Phe50Cys, Ser68Phe,
Asp92Gly, Ile113Met, Thr135Ile, Arg143Gly and Ala152Thr are
known to exist in the wider population but, to date, are not asso-
ciated with ALS in any way (Lek et al., 2016). This is despite sev-
eral occupying positions where other substitutions do cause ALS
(His46Arg and Ile113Thr, e.g.) and several non-conservative sub-
stitutions at functionally important sites (Arg143 in the copper
active site (Getzoff et al., 1983) and Phe50 in the dimerisation
region (Banci et al., 1995)). Furthermore, several SOD1 polymor-
phisms linked to ALS have a disputed role in disease pathogenesis
including Asn19Ser, Glu21Lys, Thr54Arg, Leu67Arg, Val148Ile,
Asp90Ala, Glu100Lys, Asp96Asn and Asp96Val (Mayeux et al.,
2003; Andersen et al., 2004; Felbecker et al., 2010; Fujisawa
et al., 2015). Thus, not all SOD1 mutants cause ALS and those
that do may do so irregularly. Felbecker et al. (2010) quantified
this effect and estimated that only one-third of known SOD1
polymorphisms are actually pathogenic.
SOD1 mutations within the primary and tertiary structure
Eukaryotic CuZnSOD sequence conservation is high in functional
parts of the molecule including interface, metal binding, β-barrel
core and disulphide regions, while β-strands 2, 3 and 6 on the
Fig. 4. The relationship between eukaryotic Cu/Zn superoxide dismutase codon conservation and human SOD1 ALS mutations. (a) The frequency of ALS mutations
(purple bars), non-ALS polymorphisms (orange spots) and mutations with a disputed role in ALS (green spots) in the human SOD1 primary structure. Known trun-
cation mutants are shown with black arrows and areas that differ from the wild-type sequence following a frame-shift mutation are shown in orange. The SOD1
secondary structure is also shown with β-strands coloured as in Fig. 2. (b) Consensus sequence of eukaryotic CuZnSODs. Light blue indicates identity between
human SOD1 and the eukaryotic consensus, dark blue indicates conservative substitutions and orange indicates non-conservative substitutions. (c) Human
SOD1 structure showing amino acids with >70% sequence conservation across eukaryotes highlighted in light blue. (d ) Human SOD1 amino acids ranked by eukary-
otic conservation (light blue). Sites that have at least one ALS-causing mutation are highlighted in purple. Sites that are highly conserved are more likely to have at
least one ALS mutation.
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opposing face of the β-barrel are divergent (Fig. 4b, c). Highly
conserved SOD1 residues are more likely to have associated
ALS mutations while poorly conserved residues are much less
likely to harbour ALS mutations (Fig. 4d). Fifty-seven human
SOD1 amino acids are not associated with any polymorphism,
and while they are found sparsely through-out the primary
sequence, they cluster in the β-strand 2–3 region and the
zinc-binding loop. The zinc loop and disulphide sub-loop sub-
structure within, overlaps with a region of very high sequence
conservation extending through amino acids 43–86. This indi-
cates that substitutions in the zinc loop have been sufficiently dis-
advantageous to be selected against over the whole course of
eukaryotic evolution and recent human history. Conversely,
β-strand 2–3 along with structurally adjacent β-strand 6 is an
area of high sequence divergence. This non-functional side of
the SOD1 β-barrel underwent change during early primate evolu-
tion that has been conserved in the Hominidae. The absence of
ALS mutations in this region may reflect strong recent selection
to inhibit SOD1 aggregation as is the case for other characteristics
such as charge and thermostability (Dasmeh and Kepp, 2017) or
indicate that substitutions are tolerated. The lack of sequence con-
servation and the existence of three non-ALS polymorphisms
seems to support the latter. We predict that non-ALS allelic var-
iation will be found to be high in this non-functional area of the
SOD1 β-barrel as more sequence data become available.
Some SOD1 amino acids are more frequently mutated than
others. For example, mutation of 4/4 cysteines but only 1/9 lysine
sites is known to be causative for ALS. Glycine is the most com-
mon amino acid within the SOD1 sequence (16.2%). Of the 25
glycine residues within SOD1, 15 of those sites (60%) can harbour
ALS mutations with a total of 29 different mutations. Gly93, for
example, can be found mutated to serine, valine, alanine, cysteine,
arginine and aspartic acid. Life expectancy following the onset of
disease symptoms occupies a spectrum from 2 to 10 years which
appears specific to each Gly93 substitution and also dictates the
biophysical properties of the protein (Cudkowicz et al., 1997;
Pratt et al., 2014).
Loss or gain of function?
SOD1 is abundant within motor neurons (Pardo et al., 1995);
however, reduced SOD activity of roughly 50% was quickly dis-
covered following linkage between ALS and SOD1 (Bowling
et al., 1993; Deng et al., 1993). This led investigators to suspect
that SOD1-ALS was a loss of function disease. The resulting accu-
mulation of superoxide radical, oxidative damage and mitochon-
drial pathology provided a logical route from SOD1 mutations to
neuronal death (Bowling et al., 1993). Progressing from this work,
inhibition of SOD1 by metal chelation or antisense knock-down
reduced the abundance of SOD1 protein along with SOD and
choline acetyltransferase activities. The resulting oxidative stress,
leading to apoptotic cell death, could be repressed with antioxi-
dants (Rothstein et al., 1994; Troy and Shelanski, 1994).
However, the location of ALS mutations on the SOD1 structure
ruled out a direct effect on catalysis (Deng et al., 1993).
Investigating how ALS mutations reduce SOD1 activity,
Borchelt et al. (1994) concluded that a range of specific activities
could be found for a variety of SOD1 mutants from zero up to
150% of wild-type for Gly85Arg and Gly37Arg, respectively.
However, overall Gly37Arg SOD1 activity and stability were
reduced in lymphoblasts from an fALS individual. This correlated
with the reduction of SOD1 polypeptide half-life in a cell model
with Ala4Val and Gly85Arg having the shortest at 7.5 h as
opposed to wild-type at roughly 30 h. The first biophysical char-
acterisation of disease-relevant mutations on purified protein was
performed by mapping human ALS substitutions onto S.
Cerevisiae Cu/ZnSOD (Nishida et al., 1994). On addition of cop-
per and zinc to the metal-free protein, Gly85Arg was found to
have 40% of wild-type activity while Gly93Ala had 80%. The latter
could restore insensitivity to oxidative stress in SOD1 knock-out
yeast. These results were the first indications that SOD1-ALS
does not proceed by a loss of function mechanism.
A small proportion of dominantly inherited diseases are
caused by haploinsufficiency; however, diseases with protein
loss of function are usually inherited recessively. This led to ques-
tioning of the validity of the loss of function hypothesis. A dom-
inant negative mechanism, where the mutant protein effects the
functionality of the wild-type, formed the basis of a second
hypothesis and, to this end, Gly37Arg SOD1 was shown to heter-
odimerise with wild-type (Borchelt et al., 1994). However,
Borchelt et al. (1995) found that co-expression of Gly41Asp and
Gly85Arg SOD1 mutants with wild-type did not affect the activity
or half-life of the wild-type form. Furthermore, high-level trans-
genic expression of Gly93Ala human SOD1 in mice led to an
ALS-like phenotype at 3–4 months old whereas lower expression
did not (Gurney et al., 1994). This forms a parallel with the
notion that high expression of SOD1 in spinal motor neurons pre-
disposes them to mutant SOD1-mediated cell death (Pardo et al.,
1995), and SOD1 mutants induce apoptosis in neuronal culture
where as the wild-type protein does not (Rabizadeh et al.,
1995). Borchelt et al. (1995) concluded ‘that it is unlikely that a
partial loss of free radical scavenging activity underlies motor
neuron disease in fALS’ and ‘the dominant character of
SOD1-linked fALS is due to a gain of some injurious property
of mutant SOD1 subunits’. Indeed, complete knock-out of
SOD1 does not cause ALS-like symptoms (Reaume et al., 1996).
More recently, reduced expression resulting from a 50 bp deletion
in the SOD1 promotor region was shown not to cause ALS in
humans but also does not change the ALS phenotype in people
harbouring mutant SOD1 (Ingre et al., 2013). The possible impli-
cations of SOD1 loss of enzymatic activity in ALS have been
excellently reviewed by Saccon et al. (2013) and will not be
described further.
Aggregation, a toxic gain of function
While this work was ongoing, SOD1 was found to be a compo-
nent of cytoplasmic hyaline inclusions and Lewy bodies in the
spinal cord of SOD1 fALS patients (Shibata et al., 1993, 1996a).
Bruijn et al. (1997) were then able to demonstrate the formation
of these aggregates in Gly85Arg SOD1 transgenic mice that
express the mutant protein at a level comparable with native
mouse SOD1 but which contributes little to cellular SOD activity.
The human mutant SOD1 increased in abundance as the mice
aged as opposed to the native mouse form which remained static.
They found astrocytic SOD1 Lewy-like bodies prior to ALS-like
symptom onset and they increased in number as the disease pro-
gressed. Within motor neurons, very few indistinct SOD1 aggre-
gates were observed before symptoms which progressed to
Lewy-like bodies and irregular inclusions concomitantly with
the disease. This combined evidence from mice and humans of
abnormal mutant SOD1 aggregation provided a putative gain of
toxic function to complement dominant SOD1-related fALS
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inheritance. A detailed description of SOD1 aggregates will follow
but first we look at how ALS mutations affect the SOD1 structure.
Mutant SOD1 structure and phenotype
Of the 11 ALS SOD1 substitution mutations initially discovered
by Rosen et al. (1993), six have been described by crystal struc-
tures. The complete library of crystallographic and NMR struc-
tures of SOD1 now comprises wild-type in various maturation
states and mutants from all broad groups including dimer inter-
face, β-barrel, metal-binding and loop regions. Mutants are
found in metalation states dependent on mutant characteristics,
expression platform, post-purification processing and crystallisa-
tion conditions. In some cases, mutant structures are very similar
to the wild-type but often the destabilising nature of the resulting
structural change is underestimated. The singular finding from
this painstaking biophysical characterisation is that all ALS muta-
tions frustrate molecular packing and reduce the likelihood that
SOD1 will populate the canonical mature state. There is no single
mechanism by which this destabilisation occurs, indeed every
conceivable destabilisation strategy is represented; hydrogen
bonds are weakened or broken, hydrophobic interactions are
negated and salt-bridges removed. Most frequently however, the
attractive and repulsive Van der Waals interactions which support
the SOD1 structure are disturbed and new repulsive clashes are
introduced. What follows is a dissection of the destabilising effects
found in SOD1 ALS amino acid substitution mutants available in
the Protein Data Bank (PDB) with correlation drawn to pheno-
typic data (Fig. 5). Where noted, mutations have been introduced
into the thermostable SOD1 background (Cys6Ala/Cys111Ser)
described by Parge et al. (1986).
Gly37Arg
The first structure of a mutant protein related to ALS as a whole
was the crystallographic structure of Gly37Arg SOD1 (PDB:
1AZV) (Hart et al., 1998). This mutation is found in loop III,
adjacent to the Leu38 β-barrel plug and is conserved in 96% of
eukaryotic CuZnSODs. The structure represents mature SOD1
with both metal ions and intra-subunit disulphide. The authors
observed asymmetry in copper site geometry and subunit
B-factors. As with many ALS-related SOD1 mutant structures,
the structural effect of the mutation is subtle. Comparison of wild-
type and Gly37Arg SOD1 reveals a steric clash between the Arg37
and loop I Pro13 (Fig. 6). In the wild-type form, the closest dis-
tance between these two residues, Gly37 Cα and Pro13 carbonyl
oxygen, is 3.8 Å. However, substitution for arginine would reduce
this nearest contact between Cβ and Cγ side-chain atoms to 2.3 Å.
This is well within the 3.2 Å sum of Van der Waals radii for car-
bon and oxygen atoms and would be energetically unfavourable.
As a result, the backbone of loops I and III distort to accommo-
date the 3.3 Å separation found in the crystal structure. The Arg37
side-chain has comparatively high B-factors with the exception of
the Cβ atom. While the side-chain is conformationally dynamic,
the Cβ position is dictated by the position of loop III. Therefore,
any mutation of Gly37, which by necessity incorporates an addi-
tional Cβ atom, will lead to SOD1 structural frustration and ALS.
The reported Gly37Val cases led to a 14-month and 4.6-year dis-
ease progression (Kobayashi et al., 2012; Bali et al., 2017) in con-
trast to 16.5 years mean for Gly37Arg (Cudkowicz et al., 1997;
Bali et al., 2017), possibly due to the increased repulsion presented
by two conformationally restricted carbon atoms positioned
between loops II and III rather than one.
Ala4Val
Crystallographic characterisation of Ala4Val mutant SOD1, the
most frequently occurring ALS SOD1 mutation (Cudkowicz
et al., 1997; Wang et al., 2008; Bali et al., 2017), also indicated
conservation of fold, metalation and disulphide bond but rear-
rangement around the mutation site situated close to the dimer
interface. The valine side-chain is clearly defined by electron den-
sity in thermostable (PDB: 1N19) (Cardoso et al., 2002) and wild-
type (PDB: 1UXM) (Hough et al., 2004) backgrounds as it is in
the metal-free (PDB: 3GZQ) (Galaleldeen et al., 2009) structure.
This indicates it is conformationally restricted. Introducing two
additional carbon atoms inside the tightly packed hydrophobic
core of the β-barrel pushes surrounding Phe20, Leu106, Ile113,
Ile149 and Ile151 away from the mutation site (Cardoso et al.,
2002) (Fig. 6). These permutations change inter-monomer orien-
tation (Hough et al., 2004). Mean interface Gly51-Ile151 and
Ile151-Gly114 hydrogen bonding distances are decreased 2.04 to
Fig. 5. The location of commonly studied ALS mutants
within the SOD1 dimer structure. Shown are those
mutants that have been described in crystal structures
and have phenotypic data available from more than
two cases (Wang et al., 2008).
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1.99 and 1.93 to 1.87 Å (calculated as acceptor–hydrogen distance
or 2.78 to 2.75 and 2.87 to 2.83 Å calculated as acceptor–donor dis-
tance) with concomitant changes to bond angles +1.7 and −1.4°.
Thus, on average, the Ile151-Gly114 hydrogen bond appears
strengthened by the mutation. However, the variability of
Ile151-Gly115 hydrogen bond distances and angles observed in
Ala4Val SOD1 structures is far higher than those in wild-type
structures; standard deviation 0.02–0.14 Å and 1.9–4.5°. This
describes a frustrated molecule which is not able to settle into
the tightly packed and stable structure occupied by wild-type
SOD1. Alanine is found at this position in 88% of eukaryotic
CuZnSODs; however, five other ALS-related mutations are found
at codon 4, Ala4Ser, Ala4Thr, Ala4Pro, Ala4Asp (Naruse et al.,
2013) and Ala4Phe (Baek et al., 2011). Each increases the number
of side-chain atoms within the core of the SOD1 β-barrel. While
these mutations cause variable onset of ALS, the disease course is
invariably short, 7 months to 2 years, as a result.
Gly93Ala
Gly93 is found in loop V where it is distant from metal binding,
disulphide and dimer interface regions but is conserved in 90% of
eukaryotic CuZnSODs. Six different SOD1 codon 93 mutations
are known to cause ALS: Gly93Ala, Gly93Cys, Gly93Ser,
Gly93Val, Gly93Asp and Gly93Arg with very similar mean age
at onset (47.8 years) but high variance (±14.8 years) and
mutant-specific duration variability (Gly93Ala 2.2 ± 1.5 years,
Gly93Cys 10.1 ± 6.1 years and Gly93Asp 10.5 ± 5.5 years)
(Cudkowicz et al., 1997). Comparison of metalated Gly93Ala
SOD1 (PDB: 3GZP, 3GZO, 2WKO) with wild-type SOD1
shows that introduction of the alanine Cβ would cause a steric
clash with the loop III Leu38 carbonyl (2.7 ± 0.1 Å). To mitigate
this effect, the Leu38 peptide bond rotates towards the SOD1
core increasing this distance to 3.1 ± 0.1 Å. In addition, the pep-
tide bonds of residues 92 and 93 rotate moving their carbonyls
away from the core and shifting the overall position of loop V
away from Leu38 in the loop III (Galaleldeen et al., 2009) (Fig. 6).
Leu38Val
Leu38 caps one end the β-barrel with its side-chain inserted into
the hydrophobic core. This arrangement creates stabilising Van
der Walls interactions with Val14, Ile35, His43, Ala89, Ala95,
Val119 and Leu144. It is conserved in 84% of eukaryotic
CuZnSODs. The atomic resolution crystal structure of Leu38Val
SOD1 (PDB: 2WYT) shows interactions with Ile35, Ala95,
Fig. 6. Local structural destabilisation of SOD1 by ALS mutations in crystallography. Metal binding mutants; Ala4Val shows repulsion around the mutation site while
Ile113Thr and Ile149Thr disrupt Van der Waals interactions at the dimer interface and the SOD1 core, respectively. Loop mutants; Gly93Ala causes repulsion
between loop III and loop V and Gly37Arg causes repulsion between Loop III and Loop II. β-barrel mutants; Leu38Val disrupts Van der Waals interactions in
the SOD1 core and His43Arg breaks a network of stabilising hydrogen bonds. Metal binding-region mutants; Gly85Arg causes repulsion and zinc loop disruption
whereas His46Arg prevents copper binding and destabilises the electrostatic loop. Hydrogen bonds are shown in orange lines, repulsive interactions are shown as
arrows, Van der Waals interactions are shown as dotted lines.
Quarterly Reviews of Biophysics 9
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S003358351900012X
Downloaded from https://www.cambridge.org/core. IP address: 194.66.246.18, on 25 Nov 2019 at 10:01:26, subject to the Cambridge Core terms of use, available at
Val119 are lengthened by substitution for valine, and without
rearrangement to accommodate the substitution, clashes would
be created between Val38, His43, Ala89 side chains and Gly93
carbonyl (Antonyuk et al., 2010). A favourable rotamer is selected
to minimise clashes with His43; however, the backbone must dis-
tort slightly due to repulsion between the Val38 and Ala89 side-
chains. In turn, this pushes Val14 away from the site of mutation
(Fig. 6). The overall effect of Leu38Val is therefore to reduce struc-
tural cohesion within the core of the SOD1 β-barrel. In 10% of
eukaryotic CuZnSODs, an aspartic acid substitutes for leucine
underlining the importance of maintaining packing through
Van der Waals interactions in the core of the molecule.
The Leu38Arg mutation is also associated with ALS. Here, the
extra side-chain length must create highly destabilising clashes
with the amino acids which normally form stabilising interactions
with Leu38. Phenotypic data for Leu38Arg are sparse but show
typical disease onset and progression (Millecamps et al., 2010)
while Leu38Val yields early-onset ALS with a very short disease
course. These effects are comparable with mutation of Leu106
which caps the opposite end of the SOD1 β-barrel and forms
hydrophobic Van der Waals interactions with Ala4, Phe20,
Glu22, Ile112 and Ile113. Many of these interactions would be
weakened or become repulsive on mutation to valine. Like
Leu38Val, Leu104Val gives rise to ALS with early onset and
short duration (Cudkowicz et al., 1997). Leu106Phe increases
the side-chain mass inside the SOD1 core like Leu38Arg, likely
creating clashes with Phe20 and Val29. This causes a disease
with typical age at onset but faster than usual progression
(Battistini et al., 2010).
Gly85Arg
Structural perturbations arising from substituting arginine for
Gly85 are more pronounced in comparison with those described
above. Within the SOD1 monomers found in seven available crys-
tal structures (PDB: 2VR6, 2VR7, 2VR8, 2ZKW, 2ZKX, 3CQP,
3CQQ), the mutation site adopts two different backbone confor-
mations. Eleven of 18 are found in a wild-type conformation with
the arginine side-chain extending perpendicularly from β-strand 5
and clashing with zinc loop Pro74. Alternatively, seven of 18
monomers show a 180° rotation around the Leu84 Cα-C ψ
bond, which is accommodated by a further rotation around the
Asn86 N-Cα ϕ bond, and the arginine side-chain extends towards
β-strand 6. In the latter case, zinc loop Pro74 is pushed away from
the mutation site slightly changing the position of the upper zinc
loop. In the former case, the steric clash between arginine and
Pro74 is too severe to mitigate with a similar small shift and
Pro74 rotates almost 90° (Fig. 6). This disrupts hydrogen bonding
between Pro74 and Arg79, and destabilises or reorients the upper
zinc-binding and electrostatic loops with knock-on effects on
metal binding (Cao et al., 2008). A Gly85Ser substitution has
also been observed with early onset and fast disease progression
(Takazawa et al., 2010).
Ile113Thr
Ile113Thr is the second most common SOD1 ALS mutation (Bali
et al., 2017). Ile113 residues interact across the SOD1 dimer inter-
face; Van der Waals interactions are present between the Ile113
side chain, the opposing Ile113 carbonyl oxygen and also
Gly114 Cα. These inter-molecular interactions are lengthened
by the Ile113Thr substitution (PDB: 1UXL) (Fig. 6). In addition,
new repulsive interactions are created with Ile151 side-chain and
Cys111 sulphydryl. While there are no changes to interface hydro-
gen bonding in the crystal structure of Ile113Thr, the noted effects
on interactions with Ile151 and Gly114 may affect the strength of
these bonds in solution when higher energy states are accessible.
As a result of the substitution, Cys111 adopts two side-chain
rotamers and a new loop VI conformation, which extends up to
Leu106, is stabilised in 30% of monomers. As noted by Hough
et al. (2004), a hydrophobic contact with Ala4 is also lost leading
to destabilisation compared to wild-type. These structural changes
resulting from the mutation are subtle, and while Ile113 is con-
served in 58% of eukaryotic CuZnSODs, it is often replaced by
valine or leucine indicating a tolerance of these conservative sub-
stitutions. This is reflected in late disease onset, longer than aver-
age disease course and incomplete penetrance (Suthers et al.,
1994; Cudkowicz et al., 1997).
Ile149Thr
The Ile149 side-chain Cδ1 has Van der Waals interactions with
Val47, Ile112, Val148 and Leu117. The structure of Ile149Thr
in a thermostable background (PDB: 4OH2) shows space is cre-
ated in the core of the molecule on mutation to threonine and
these hydrophobic interactions are lost. Ile112 relaxes into the
newly available space as does the Arg115 peptide bond carbonyl
which rotates, possibly weakening the hydrogen bond with
Arg115 which links β-strands 7 and 8 (Fig. 6). Ile113 and
Ile149 are foundation residues, they serve only structural pur-
poses, there are no serious repulsive clashes generated by the con-
servative mutations described but a vacuum is created in the
molecule which undermines structural cohesion.
His43Arg
His43 is found on β-strand 4 and forms strong hydrogen bonds
with Thr39 in loop III and the copper coordinating ligand
His120 in loop VII, the electrostatic loop. Held in this position,
His43 provides support to Leu38 through Van der Waals interac-
tions. The crystal structure of His43Arg, in a thermostable back-
ground (PDB: 1PTZ), shows the arginine maintaining hydrogen
bonding with Thr39 and making a further hydrogen bond with
Glu40 through its side-chain guanidinium group but loses the
interaction with His120. To avoid a major steric clash with loop
III, the Arg43 side-chain adopts a rotamer shifted away from
Leu38 (Fig. 6). This reduces buried packing surface between the
two residues fivefold and removes many of the Van der Waals
interactions provided by His43 (DiDonato et al., 2003).
His46Arg
His46 coordinates copper in the SOD1 active site and as a result is
ubiquitously conserved across eukaryotic CuZnSODs. Large ter-
tiary structure defects arising from His46Arg mutation are clear
in crystallo (PDB: 1OZT and 1OEZ); in both metal-free and zinc-
bound states, the electrostatic and zinc-binding loops are destabi-
lised which enables non-native loop and β-barrel interactions
between neighbouring molecules (Elam et al., 2003a). This results
from: (1) Lost His71-zinc coordination, changing both geometry,
position and very likely affinity for zinc. (2) Clashes with copper
and zinc coordinating His63 pushing it away from the site of
mutation with similar effects. (3) Clashes with electrostatic loop
Asp124, Thr137 and Ala140 (Fig. 6). His46Arg SOD1-related
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ALS presents at the typical age for SOD1 ALS but has a very long
disease course which can last more than 20 years (Aoki et al.,
1993; Bali et al., 2017). Please see ‘Structural instability’ for a dis-
cussion of the relationship between His46Arg stability and
phenotype.
Ser134Asn, Asp125His, Asp124Val and His80Arg
The electrostatic loop mutation Ser134Asn has much the same
effect on SOD1 as His46Arg despite the very different location
(Elam et al., 2003a). While the Asn134 residue itself cannot be
seen in the crystal structure (1OZU) due to disorder in the elec-
trostatic loop, the reasons are clear; severe clashes with loop res-
idues 125, 127–131 which prevent adoption of the canonical
helical structure. Ser134 mutation to asparagine prevents adequate
metal binding leading to hydrophobicity, abnormal intermolecular
contacts and aggregation (Hayward et al., 2002; Elam et al., 2003a;
Banci et al., 2005; Marucci et al., 2007). Counterintuitively however,
the Ser134Asn phenotype is not aggressive despite the above
molecular characteristics. Two heterozygous individuals developed
late-onset ALS (63 and 52 years old) with variable progression (9
months and at least 2 years) while another heterozygous individual
had no symptoms at 70 years old (Watanabe et al., 1997; Marucci
et al., 2007). A fourth individual, who had trisomy 21 Down’s syn-
drome and two copies of the Ser134Asn SOD1 allele, developed
ALS at 34 years of age which progressed over 3 years (Marucci
et al., 2007) and is reminiscent of the gene dosage effect observed
in homozygous Asp90Ala ALS patients.
The crystal structure of Asp125His (PDB: 1P1V) (Elam et al.,
2003b) shows very similar destabilisation of the electrostatic loop
between amino acids 129 and 135 as described for Ser134Asn.
This is due to steric clashes with Gly126, Ser134 and Asn139
that prevent folding of the electrostatic loop helix. The clash
with Ser134 causes the mutated His125 to flip rotamer and project
into the solvent in two of three cases. In addition, a hydrogen
bond which links Gly127 and the Asp125 side-chain is broken.
Individuals with this mutation died of ALS at age 57 and 71,
the latter following a 20-month disease duration (Enayat et al.,
1995).
Asp124Val also causes destabilisation of electrostatic loop res-
idues 124–139 and upper zinc loop amino acids 66–79. The crys-
tal structure of this mutant (PDB: 3H2P) shows the bonding
network which links copper coordinating His46 through
Asp124 to zinc coordinating His71 is lost on mutation to valine
(Seetharaman et al., 2010). This removes a vital stabilising link
between the β-barrel core, disulphide sub-loop and electrostatic
loop. Metal binding is consequently compromised.
His80Arg is the only verified de novo SOD1 mutation known
to have caused ALS. Crystal structures of His80Arg SOD1 (PDB:
3QQD and 3H2Q) show destabilisation of the upper zinc and
electrostatic loops due to complete loss of the zinc site and severe
steric clashes with both His71 and Lys136 (Seetharaman et al.,
2010). His80Arg has been found in only one person who pre-
sented with ALS symptoms at 24 years of age and died 18 months
later (Alexander et al., 2002). This early disease onset would
reduce the propagation of this mutation through future genera-
tions and illustrates that the majority of SOD1 mutations have
been able to persist because they generally cause disease after
the reproductive period of human life.
His46, His80, Ser134, Asp125 and Asp124 are ubiquitous
across eukaryotic CuZnSODs. With the exception of His80, muta-
tion of these residues gives rise to forms of ALS where the disease
presents late in life or with a protracted disease course. These
mutations, to very highly conserved amino acids, often scramble
or completely prevent important metal binding and manifest as
phenotypically less severe than Leu38 and Leu106 mutant ALS.
Mutations outside of the β-barrel core and dimerisation regions
appear better tolerated by some molecular or cellular mechanism.
SOD1 maturation and ALS mutants
Following ribosomal translation, the progression from nascent
and unfolded protein to the active and mature enzyme is crucially
important in the production of SOD1. This post-translational
maturation pathway includes folding, metal binding, intra-
subunit disulphide formation and dimerisation. Appraisal of the
mutant SOD1 crystal structures described above in conjunction
with a wealth of biophysical, biochemical and cell biology research
reveals common themes of structural instability, incomplete or
aberrant metalation, disulphide reduction, dimerisation defects
and propensity to exist in an unfolded state. Below we review
the post-translational processes in the sequence they are likely
to occur within cells and highlight how the different steps can
be affected by ALS mutations paying particular attention to
those SOD1 mutants which do not fit overall trends.
Folding
SOD1 folding can happen spontaneously or aided by the human
copper chaperone for SOD1 (hCCS), but does not require
ATP-dependent chaperones (Bruns and Kopito, 2007; Luchinat
et al., 2017). By analysing protease K-catalysed degradation fol-
lowing SOD1 translation, Bruns and Kopito (2007) showed that
copper binding has no effect on folding. Conversely, removal of
zinc from the folding environment prevents transformation into
a highly protease-resistant form but not a moderately resistant
intermediate. This is indicative of a two-step folding mechanism
that comprises sequential zinc-independent β-barrel formation
and zinc-dependent loop ordering. Analogously, using chaotropic
unfolding, Lindberg et al. (2004, 2005) described a two-step fold-
ing mechanism for metal-free SOD1 with the denatured mono-
mer folding independently through a transition state prior to a
dimerisation event. Monomer folding is slow when compared
to other two state proteins but in as expected for highly
β-structure-rich proteins (Kayatekin et al., 2012). Folding is the
rate-limiting step and subsequent dimerisation is limited only
by diffusion. Different SOD1 mutations perturb either one or
both of the steps in this process and drive the protein towards
immature states (Lindberg et al., 2005).
Folding in the presence of zinc is faster than for the metal-free
SOD1; however, the low affinity of the nascent protein for zinc
may mean folding occurs slowly through metal-free species and
zinc is bound later (Kayatekin et al., 2008). Metal-free SOD1
monomer folding is nucleated by hydrophobic side-chain interac-
tions within the core of the β-barrel on β-strands 1, 2, 3, 4 and 7
(Nordlund and Oliveberg, 2006) (Fig. 7). This folding nucleus
operates independent of loop structures and metal binding with
the enthalpic barrier to monomer folding related to the dehydra-
tion of these hydrophobic core residues (Kayatekin et al., 2012;
Yang et al., 2018). The primary sequence distance between
β-strands 4 and 7 (70 residues) offers a rationale for the relatively
slow folding of β-rich SOD1 and the susceptibility for aggregation.
The retention of N-terminal β-strands in the core of SOD1 aggre-
gate structures could also be a facet of their swift assembly
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following translation while other strands involved in the transition
state structure leave the ribosome much later.
Metal binding
SOD1 is thought to acquire free zinc from its surroundings while
copper is acquired from hCCS or an hCCS-independent route
(Subramaniam et al., 2002; Carroll et al., 2004). Zinc binding
may occur in the free monomer state, or following
chaperone-assisted folding when complexed with hCCS (Potter
et al., 2007; Kayatekin et al., 2008; Leinartaite et al., 2010; Banci
et al., 2013; Boyd et al., 2018). The canonical β-barrel fold of
mature wild-type SOD1 is retained on the removal of metal cofac-
tors under test-tube conditions (Wood et al., 1971). In the metal-
free state, the electrostatic and zinc loops have a high degree of
disorder; however, lack of copper metalation does not signifi-
cantly change the loop structure (Strange et al., 2003; Sekhar
et al., 2015). The stabilising effect of zinc was discovered by
Forman and Fridovich (1973), and our understanding of loop
ordering on zinc binding reinforces that notion. However, zinc
also positions the redox potential of the copper ion to enable cat-
alytic cycling between Cu(I) and Cu(II) states (Nedd et al., 2014).
Furthermore, characterisation of Candida albicans SOD5 super-
oxide dismutase showed this enzyme has an intact copper site
but ALS-like mutations to zinc site His71 and His80 (human
numbering) which prevent zinc binding (Gleason et al., 2014).
As a result, C. albicans SOD5 has reduced copper affinity com-
pared with other CuZnSODs (Robinett et al., 2018). SOD5 is an
extracellular enzyme which likely gains its metal cofactor through
release of copper during host oxidative burst. Conversely, intracel-
lular CuZnSODs, including human SOD1, must compete for cop-
per with the high chelation capacity of the cellular interior
making zinc binding a necessity. Thus, zinc binding serves roles
in folding, stability, copper acquisition and catalysis.
The absence of free copper salts in biological systems was pos-
ited by Mann and Keilin (1938a) at the outset of SOD1 research.
The intracellular chelation capacity of yeast, for example, means
that of the estimated 390 000 copper atoms present in the cell,
less than one ion exists free in solution (Rae et al., 1999). To
service demand for the SOD1 copper cofactor, a relay system is
necessary in order to prevent intra-cellular metal scavengers
from limiting supply. Proteins responsible for the cellular traffick-
ing of metals are termed metallochaperones and act primarily as
sequestration and transport devices. Metallochaperones assist in
the prevention of incorrect metal ion coordination resulting
from the preference of metal binding proteins to coordinating
metals at the high end of the Irving–Williams series.
Sequestration also mitigates the hazard of reactive metals in solu-
tion, the case in point being free radical production by copper
through redox chemistry.
Identification, structure and function of hCCS
The discovery of HAH1 and COX17 copper chaperones for the
copper transporting P-type ATPases and cytochrome c oxidase,
respectively, spurred the search for a protein that activated
SOD1 with copper. Culotta et al. (1997) discovered the copper
chaperone for SOD1 (CCS) through the similarity of SOD1 and
LYS7 yeast knock-out strains’ oxygen-dependent inability to syn-
thesise lysine and methionine. hCCS was discovered by EST
sequence comparison with LYS7 and found to be expressed in
all human cell types. Within the central nervous system, hCCS
was found to be relatively abundant within motor neurons,
deep cerebellar neurons and cortical neurons overlapping the dis-
tribution of SOD1 (Rothstein et al., 1999).
hCCS comprises two distinct domains which are connected by
flexible linkers that allow a high degree of conformational free-
dom. In addition, an extended, largely unstructured region is
found at the C-terminus (Wright et al., 2011; Sala et al., 2019).
hCCS domain II (amino acids 86–234) is 47% identical to
human SOD1 (Culotta et al., 1997; Casareno et al., 1998).
Crystal structures of hCCS show that domain II has an anti-
parallel Greek-key β-barrel and harbours a dimerisation interface
very similar to that of SOD1 (Lamb et al., 1999; Sala et al., 2019).
This SOD1-like domain mediates a direct interaction with SOD1
(Casareno et al., 1998). While zinc binding is conserved between
SOD1 and hCCS domain II, copper binding is not (Schmidt et al.,
1999). Furthermore, loss of zinc prevents hCCS homodimerisa-
tion and heterodimerisation with SOD1 thereby reducing its
Fig. 7. The SOD1 folding pathway. Step 1: Nascent and completely unstructured SOD1 folding is nucleated by residues in β-strands 1, 2, 3, 4 and 7. Step 2: The
molecular chaperone activity of hCCS then promotes folding of the remaining β-barrel structure and disulphide subloops. Step 3: SOD1 binds zinc and disulphide
formation imparts stability on the disulphide sub-loop. This weakens hCCS-SOD1 heterodimer affinity. Step 4: Strong SOD1 interface Gly51-Ile151 hydrogen bond-
ing and a stable dimer interface both promote SOD1 homodimerisation. Steps 5 and 6: hCCS mediated folding can be circumvented through spontaneous β-barrel
organisation and zinc binding however the mechanism of disulphide formation, and therefore the formation of a stable dimer interface, through this
hCCS-independent route is not entirely clear. SOD1 β-strands are coloured as in Fig. 2.
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ability to activate SOD1 (Endo et al., 2000; Allen and Dennison,
2014; Wright et al., 2016).
The first 85 amino acids, domain I, of hCCS and yCCS are
homologous to the Atx1-like copper-binding proteins and contain
the consensus MHCXXC copper (I)-binding motif which is pre-
sent in HAH1, ATOX1, and both copper-transporting ATPases.
Domain I binds copper (I) in a bis-cysteine arrangement with
1015 to 1018 M affinity (Brown et al., 2004; Banci et al., 2010,
2012a; Allen et al., 2012b) without significant main chain or
side chain perturbations by comparison of NMR structures
PDB: 2CRL and 2RSQ produced by the Yokoyama and Banci
groups, respectively. The affinity of domain I for copper is less
than that of the tetra/tri-histidine SOD1 site, therefore copper
flow along the hCCS trafficking route is uni-directional (Banci
et al., 2010). Heterodimer formation between SOD1 and hCCS
along with the concerted action of domain I and a CSC motif
in the C-terminal tail facilitates the delivery of both copper and
the disulphide bond to the immature SOD1 substrate (Culotta
et al., 1997; Furukawa et al., 2004).
The role of hCCS in SOD1-ALS
Mouse CCS knock-out does not change disease onset or life span
in Gly37Arg, Gly93Ala and Gly85Arg SOD1 transgenic mice
(Subramaniam et al., 2002). Conversely, overexpression of hCCS
in a mutant SOD1 background has a profound negative effect
on disease; Gly93Ala SOD1/hCCS double transgenic mice have
a mean survival of 36 days in comparison with 242 for single
transgenic Gly93Ala SOD1 mice (Son et al., 2007; Proescher
et al., 2008). Reduced life span is associated with quickly appear-
ing vacuolar mitochondrial pathology. This is of note because
CCS can direct SOD1 to the mitochondria where aggregation
on membranes or within the intermembrane space is observed
in ALS mutant cell and animal models (Deng et al., 2006;
Kawamata and Manfredi, 2008; Vande Velde et al., 2008; Oladzad
Abbasabadi et al., 2013). In contrast, transgenic mice over express-
ing hCCS or wild-type SOD1/hCCS have normal life-span with no
mitochondrial swelling (Son et al., 2007). Supplementation of cop-
per effectively confers wild-type-like survival of Gly93Ala SOD1/
hCCS overexpressing mice (Williams et al., 2016).
Incomplete metalation
Incomplete SOD1 metalation as a result of metal-binding ligand
substitution was first observed by Banci et al. (1991), prior to
the establishment of a link between SOD1 and ALS. One of the
mutations described, Asp124Gly, was later shown to be associated
with ALS (Andersen et al., 2003). Following linkage with ALS,
Deng et al. (1993) predicted that the Gly85Arg SOD1 mutation
would disturb His46 and Asp83 metal site co-ordinating ligands.
This was proven shortly after by incorporating the mutation into
yeast CuZnSOD (Nishida et al., 1994). Gly85Arg SOD1 activity
was lost on addition of stoichiometric amounts of ethylenedi-
aminetetraacetic acid, whereas wild-type and Gly93Ala retained
their activity after the addition of more than 2000-fold excess.
Visible light electronic absorption spectroscopy confirmed that
zinc site geometry had indeed been compromised by the
Gly85Arg substitution.
With the exception of the bridging ligand His63, every metal
coordinating ligand (His63, His48, His71, His80, Asp83 and
His120) has been found mutated in cases of ALS. On examination
of the crystal structures of SOD1 where mutations are found in
metal coordinating residues or close to metal sites, there is clear
and rationalisable loss of metal cofactors. However, many
non-metal-binding region SOD1 mutations including Ala4Val,
Leu39Val, Gly41Ser, GLy85Arg, Ile113Thr, Gly37Arg and
Gly72Ser also have reduced metalation when expressed in heterol-
ogous systems (Hayward et al., 2002; Luchinat et al., 2014).
Furthermore, metal-free, disulphide-reduced Gly85Arg, His46Arg,
Val148Gly and Glu100Gly SOD1 variants do not adopt a transient
electrostatic loop conformational sub-population found in 2% of
the metal-free, disulphide-reduced wild-type protein (Sekhar
et al., 2015) that resembles the helix found in the mature protein.
In the case of Ala4Val, Gly93Ala and Gly37Arg access to this con-
formation is partially restricted (Sekhar et al., 2016). While this
helix does not contain any of the zinc coordinating residues, it
folds adjacent to the zinc site and may aid acquisition of zinc.
On addition of zinc, the electrostatic loop loses its conformational
plasticity coalescing into the conformation found in the mature
form (Strange et al., 2003; Culik et al., 2018).
The dissociation constants for zinc and copper binding to wild-
type SOD1 were determined to be 10−14 and 10−18 M−1, respec-
tively (Crow et al., 1997). Eighteen to 30-fold reduction in zinc
affinity for Ala4Val, Ala4Thr, Ile113Thr and Leu38Val SOD1
was demonstrated while the reduction in copper affinity was
much less severe. Within cells, and even with supplementation of
growth media with zinc, many of these mutants fail to adequately
zinc metalate and remain in an unstructured state (Luchinat et al.,
2014). Absence of metals leads to the formation of high molecular
mass SOD1 aggregates on incubation of purified protein at body
temperature (Banci et al., 2007; Wright et al., 2013). Mutant
SOD1 found in the soluble fraction of transgenic mouse spinal
cords is metalated, albeit with perturbed Cu:Zn ratio. However,
analysis of aggregates from mutant SOD1 transgenic mice spinal
cord indicated no increase of copper or zinc content despite
increased SOD1 content. Thus, the SOD1 that accumulates in
aggregates is metal free (Lelie et al., 2011). Additionally, several
SOD1 conformation-specific antibodies, including the first
described C4F6 that was raised against and specific for metal-free
mutant SOD1, recognise their epitope in human ALS spinal tissue
and lysates (Urushitani et al., 2007; Brotherton et al., 2012).
Disulphide bond
Wood et al. (1971) showed that removing metal cofactors and the
disulphide bond from SOD1 led to the loss of secondary and ter-
tiary structure. While SOD1 monomers will adopt their β-barrel
fold in the absence of the intra-subunit disulphide, its presence sta-
bilises the monomer and promotes dimerisation (Lindberg et al.,
2004). Conversely, formation of the disulphide can promote acqui-
sition of structure from an otherwise globally unfolded precursor
through an oxidative folding mechanism (Capper et al., 2018).
SOD1 must form and maintain its disulphide in the presence of
reduced glutathione and the thioredoxin system which are pur-
posed to reduce cytoplasmic thiols. When over-expressed in
human cell culture, SOD1 does not naturally form the disulphide.
Conversely, half of SOD1 monomers form the disulphide on
co-expression with hCCS. Addition of copper to this system yields
complete disulphide formation (Banci et al., 2013).
The role the SOD1 intra-subunit disulphide plays in stabilisa-
tion and dimerisation is made clear in structures of the wild-type
protein. Covalent bonding of Cys146, found in β-strand 8, to
Cys57 anchors the zinc loop to the core of the protein. The disul-
phide sub-loop, a component of the zinc-binding loop IV, is
defined by copper-coordinating His48 and metal-bridging ligand
His63 at its N- and C-termini. The disulphide subloop forms 62%
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of the buried surface area of the SOD1 dimer interface (Fig. 8a)
and also contains Gly51 which creates two of the four interface
hydrogen bonds (Fig. 3). We have recently shown disulphide sub-
loop plasticity to also be a necessary precursor of heterodimerisa-
tion with hCCS (Sala et al., 2019).
Lyons et al. (1996) showed that mature Ala4Val, Gly85Arg and
Gly93Ala SOD1 are less resistant to intra-subunit disulphide
reduction on exposure to ascorbate than the wild-type form.
Indeed, all SOD1 mutants are more susceptible to disulphide
loss in a reducing environment akin to the cytoplasm, promoting
monomerisation and loss of structural cohesion. This effect is
more pronounced for metal-binding region mutants and metal-
free wild-type SOD1 (Tiwari and Hayward, 2003). In addition,
Alvarez-Zaldiernas et al. (2016) showed that a reconstituted thio-
redoxin system was capable of reducing Ala4Val and Gly93Ala
disulphides. This disulphide-reduced SOD1 is observed in
SOD1 transgenic mice, particularly in the brain and spinal cord
(Jonsson et al., 2006a), and is a major component of intracellular
aggregates (Karch et al., 2009).
The mean S–S length within a protein disulphide bond is 2.02–
2.04 Å (Thornton, 1981; Petersen et al., 1999). The S–S distance var-
iation across every SOD1 half cystine pair found in the PDB shows a
mode at 2.04 Å with a long tail stretching out to 2.82 Å (Fig. 8b).
SOD1 intra-subunit S–S bond lengths above 2.3 Å are found in
His46Arg/His48Gln double mutant (PDB: 3GQF) (Winkler et al.,
2009), Gly85Arg (PDB: 3CQP) (Cao et al., 2008), Gly93Ala (PDB:
3GZO) (Galaleldeen et al., 2009) and His80Arg SOD1 crystallo-
graphic structures (PDB: 3H2Q and 3QQD) (Seetharaman et al.,
2010). These structures are well refined with resolutions of ∼1.95 Å.
It is very likely that these S–S bonds have been broken through expo-
sure to x-rays as is the case for some disulphides found in the
Ile113Thr SOD1 structure (PDB: 1UXL) (Hough et al., 2004). This
underscores the fragility of the mutant SOD1 disulphide bond and
the importance of accounting for radiation damage in published crys-
tal structures. Omitting these bonds gives a mean SOD1 disulphide
bond S–S distance of 2.08 Å, similar to the 2.05 Å distance observed
in bovine SOD structures (Hough et al., 2000).
Dimerisation
SOD1 dimerises through portions of β-strands 1, 8, loop VI and
the disulphide subloop section of loop IV. Due to primary
sequence separation of the N- and C-termini, SOD1 cannot
dimerise before translation is complete. The interface is hydro-
phobic and excludes water. Ile151 residues create hydrogen
bonds with Gly51 and Gly114 from the opposing monomer cre-
ating four interfacial hydrogen bonds. Overall, SOD1 dimer inter-
face mutations disturb dimer interface packing but do not affect
these bonds. Exceptions to this rule include hydrogen bond length
variability for Ala4Val SOD1 which manifests as dimer reorienta-
tion, described in ‘Ala4Val’ section and Hough et al. (2004), and
C-terminal truncations which remove Ile151 and therefore all
interface hydrogen bonding.
As with the post-translational modifications described in the
previous sections, homodimerisation increases SOD1 stability;
obligate monomer SOD1 unfolds at lower chaotrope concentra-
tion than the dimer (Lindberg et al., 2005). In vivo, dimerisation
occurs after zinc binding and disulphide formation but in solution
any state of wild-type SOD1 can be forced to dimerise by increas-
ing its concentration (Arnesano et al., 2004; Bruns and Kopito,
2007; Hörnberg et al., 2007). When the SOD1 disulphide is
reduced, the zinc-binding loop becomes dynamic and dimer
affinity is reduced (Banci et al., 1998). Conversely, SOD1 homo-
dimer affinity is increased by progressively restricting zinc loop
and disulphide subloop conformational sampling as SOD1
acquires post-translational modifications (Hörnberg et al.,
2007). The reciprocity of dimerisation and disulphide bonding
is illustrated by crystal structures where both disulphide bonding
cysteines are mutated to alanine. In these cases, promoting dimer-
isation through high concentration forces the disulphide subloop
to adopt the conformation common to disulphide intact struc-
tures (Hörnberg et al., 2007; Sala et al., 2019).
The homodimer dissociation constant for mature wild-type
SOD1 is in the low nanomolar to high picomolar range (10−8
to 10−10 M) (Khare et al., 2004; McAlary et al., 2013). Many
SOD1 ALS mutants, including Gly93Ala, have dimer affinity
equal to that of wild-type but dimer interface mutants Ala4Val,
Val148Gly and Ile149Thr reduce this affinity (McAlary et al.,
2013; Capper et al., 2018). The metal-free, disulphide-intact, wild-
type SOD1 dimer dissociation constant is high nanomolar and
every mutant tested by Broom et al. (2015a) was destabilised by
up to 3-orders of magnitude with homodimer affinity ranging
up to 100 µM. As a result, reduced mutant homodimer formation,
and indeed heterodimer formation with wild-type SOD1, is
Fig. 8. The SOD1 disulphide sub-loop dimer interface. (a) The disulphide subloop forms extensive contacts across the SOD1 dimer interface. (b) S–S bond lengths
found in all human SOD1 structures in the Protein Data Bank. The 2.02–2.04 Å average for all protein structures (Thornton, 1981; Petersen et al., 1999) is shown in
grey. By excluding bond lengths above 2.3 Å the mean SOD1 S–S bond length is found to be 2.08 Å, shown in blue.
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observed within cells for all SOD1 mutants with the exception of
Asp90Ala (Kim et al., 2014). Additionally, an antibody raised
against amino acids 143–151 in β-strand 8 that are only accessible
when SOD1 is monomeric recognises its antigen in transgenic
rodent and human ALS spinal cord samples. Immunoreactivity
was highest for mitochondrial tissue fractions, particularly those
from Gly85Arg mice, despite mitochondrial SOD1 being only a
small component of total cellular SOD1. Tissues were stained
increasingly through presymptomatic and initial symptom onset
but declined at disease end stage (Rakhit et al., 2007).
Reducing the affinity of metal-free SOD1 homodimerisation
does not necessarily mean increased populations of unfolded
monomers. Ala4Val, His46Arg and Val148Gly can all exist as
folded monomers (Broom et al., 2015b). The existence of mono-
meric immature SOD1 with a conformationally flexible disulphide
loop is also a prerequisite for the formation of a transient hetero-
dimer with hCCS (Sala et al., 2019). We do not know if the affinity
of hCCS for its substrate is altered by ALS SOD1 mutations but
there is evidence that some mutants are not able to interact with
hCCS while others form stable complexes (Son et al., 2009). It is
likely that mutation-dependent SOD1 homodimer affinity changes
will also be reflected in the interaction with hCCS.
Structural instability
SOD1 zinc metalation, disulphide formation and dimerisation
synergistically raise SOD1 thermal stability (Furukawa and
O’Halloran, 2005). However, SOD1 nascent state stability is com-
promised by long, metal-binding loops. Shortening these func-
tional structures increases metal-free, disulphide-reduced SOD1
stability (Yang et al., 2018). This trade-off between functionality
and stability is represented throughout nature. For example, pro-
teins from thermophiles tend to have trimmed loops. Closer to
our subject, C. albicans SOD5 and the S. cerevisiae CCS
SOD-like domain have substantially shorter electrostatic loops
in comparison with human SOD1 and the hCCS SOD-like
domain, respectively, because the former does not bind zinc
(Culotta et al., 1997; Gleason et al., 2014). Having shorter func-
tional loops increases nascent-state stability but effective zinc
binding has clearly outweighing functional benefits for SOD1.
The concept of reduced SOD1 metalation leading to structural
instability was first described by Wood et al. (1971). ALS mutants
are less resistant to chaotropic unfolding in both the metal-free
and metalated states (Lindberg et al., 2002; Stathopulos et al.,
2003). This work led Lindberg et al. (2002) to propose that desta-
bilisation leads to aggregation, while Stathopulos et al. (2003) sub-
sequently correlated decreased thermal stability, unfolding and
aggregation.
Rodriguez et al. (2002) described reduced thermal stability of
recombinant ALS SOD1 mutants in comparison with wild-type
in metalation states as-isolated from insect cells. Furukawa and
O’Halloran (2005) noted that the 42.9 °C melting temperature of
nascent wild-type SOD1, lacking both disulphide and metal ions,
is above physiological temperature and sequential addition of
zinc (58.4 °C) and the Cys57-Cys146 disulphide (74.6 °C) incre-
mentally increases thermal stability. Thus, wild-type SOD1 thermal
stability increases as it progresses along the maturation pathway
from metal-free, disulphide-reduced, monomeric protein to the
fully metalated, disulphide intact, dimeric, active enzyme.
Increased dimer affinity, reduced populations of excited states
and increased thermal stability are reflected in increased enzymatic
activity and half-life (Furukawa and O’Halloran, 2005; Culik et al.,
2018). Importantly, Gly93Ala and Ala4Val ALS substitutions
reduced the melting temperature of the nascent protein below
physiological temperature as ascertained by differential scanning
calorimetry (DSC) experiments (Furukawa and O’Halloran,
2005). This is indicative that these species exist in a monomer
unfolded state which was later observed by hydrogen/deuterium
exchange and native mass spectrometry along with in-cell NMR
for a range of mutants including Ala4Val and Gly93Ala (Shaw
et al., 2006; Luchinat et al., 2014; McAlary et al., 2016).
Progression along the normal maturation pathway can stabilise
SOD1 mutants in vitro, but frequently not to the same extent as
wild-type, and this process is often ineffective within cells
(Furukawa and O’Halloran, 2005; Luchinat et al., 2014).
The majority of ALS-related SOD1 mutations have been
shown to be thermally destabilising in all states where testing
was possible (Rodriguez et al., 2002; Stathopulos et al., 2003;
Furukawa and O’Halloran, 2005; Münch et al., 2011; Vassall
et al., 2011; Doyle et al., 2016). The immature state is where the
biggest stability deficits are found (Furukawa and O’Halloran,
2005; Kayatekin et al., 2010) but destabilisation of the apo state
is not the whole story. Metal site mutants are equally, if not
more stable than wild-type, when metal free (Rodriguez et al.,
2005).
While metal-free, disulphide intact His46Arg SOD1 has been
shown to have similar thermal stability compared to wild-type
(Münch et al., 2011; Abdolvahabi et al., 2017). The metal-free,
disulphide-reduced state is stabilised by 5 °C possibly affording it
resistance to accumulation into large aggregates (Vassall et al.,
2011). His46Arg SOD1 is not unusual in this regard, Nordlund
et al. (2009) showed that mutation of all four zinc coordinating res-
idues stabilises the immature protein. Unlike non-metal-binding
site ALS mutants, however, His46Arg and His48Gln cannot pro-
gress along the normal maturation pathway to reach full stability
and activity (Hayward et al., 2002; Bruns and Kopito, 2007). This
strands His46Arg in a pseudo-stable state with a nearly 30 °C ther-
mal stability deficit in comparison with mature, wild-type SOD1
perhaps enabling degradation. His46Arg SOD1-related ALS has a
long disease course, possibly due to these characteristics.
The Val148Ile dimer interface substitution has been shown to
thermally stabilise the metal-free, disulphide-reduced state by 5 °C
(Vassall et al., 2011) but conversely its homodimerisation affinity
is decreased sevenfold (Broom et al., 2015a). DSC experiments
performed on mature Val148Ile SOD1 show no difference in
melting temperature over a range of protein concentrations but
amide proton chemical shift temperature coefficients describe sta-
bilisation across the protein sequence (Doyle et al., 2016). We also
note that, like wild-type, Val148Ile SOD1 is not recognised by a
misfolding-specific antibody targeting the Derlin-1 binding site
in the SOD1 N-terminus possibly because of the above stabilisa-
tion (Fujisawa et al., 2015). Total erythrocyte Val148Ile SOD1
activity was found to be ∼58% of controls, indicative of decreased
half-life in common with other destabilised ALS mutants
(described in the following section). While only one individual
is known to have carried the Val148Ile mutation (Ikeda et al.,
1995), inheritance in that individual’s family was clearly domi-
nant with disease onset very young with rapid progression
(Sakuma et al., 1995). Together, this is indicative of genuine
SOD1-ALS. However, and as is often the case with SOD1-ALS
mutations, drawing conclusions on causality from patients with
very low-frequency alleles is challenging.
SOD1 like most proteins exists within a heterogenous soup of
water, ions, small molecules and macromolecules within our cells.
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This molecular crowding can have varied effects on proteins
under investigation (Ma et al., 2012). However, the SOD1
β-barrel is generally destabilised by the cellular environment
when compared with purified protein in aqueous buffer. In
some cases, this can reduce its folding transition temperature by
40% (Danielsson et al., 2015; Bille et al., 2019). The change in
stability conferred by the environment occurs through interac-
tions with β-strands 6 and 8 that stabilise the unfolded state
(Bille et al., 2019). As such, environmental effects are strongly
determined by the primary sequence. SOD1 ALS-like mutations
largely exacerbate the overall destabilising trend on the β-barrel
with the exception of His46Arg which has very slightly increased
stability (Gnutt et al., 2019). This again highlights the cost-benefit
relationship of introducing functionality. The conclusion of this
work is that SOD1 species which appear folded under test-tube
conditions may well be unfolded at physiological temperatures
within cells. The adoption of a persistently unfolded state for
many metal-free SOD1 ALS mutants in the cytoplasm is the result
(Luchinat et al., 2014).
Activity and degradation
The final step in SOD1 maturation yields a stable and active
enzyme. However, erythrocyte SOD1 activity is almost always
reduced in ALS patients (Saccon et al., 2013; Keskin et al.,
2017). Exclusion of Asp90Ala mutants leads to a mean activity
of roughly 50% of that found in non-ALS individuals. Clearly
an inability to correctly metalate will reduce overall SOD1 activity
but a second, related factor may also play a role. Sato et al. (2005)
found erythrocytes taken from people heterozygous for an ALS
SOD1 mutations had reduced abundance (0–58%) of the mutant
SOD1 protein. Wild-type SOD1 is a long-lived protein with a
25-day half-life in cerebrospinal fluid. In transgenic rats, spinal
cord wild-type SOD1 has a 15-day half-life whereas Gly93Ala
SOD1 has a half-life of 9 days (Crisp et al., 2015). Mutant
SOD1 is also turned-over faster than wild-type in cell-based
assays (Nakano et al., 1996; Kabuta et al., 2006). Mature red
blood cells do not contain a nucleus and therefore cannot tran-
scribe new mRNAs encoding cellular proteins. Thus, it appears
that no new SOD1 is created but mutant SOD1 is preferentially
degraded. Over the life-time of a red blood cell, this reduces the
abundance of mutant SOD1. In general, SOD1 degradation pro-
ceeds by proteasomal or macroautophagic routes (Kabuta et al.,
2006; Keskin et al., 2016). Ubiquitin E3 ligases dorphin, CHIP,
mahogunin and cIAP have all been shown to ubiquitinate mutant
SOD1 and signal its degradation (Choi et al., 2004, 2016; Sone
et al., 2010; Chhangani et al., 2016). However, SOD1 aggregation
has been shown to sequester more than half of cellular ubiquitin
thereby reducing the availability of free monomeric ubiquitin with
downstream changes to the ubiquitination profile of more than 70
cellular proteins (Farrawell et al., 2018). Thus, ALS SOD1 mutants
that cause the greatest structural disturbance and instability lead
to the greatest reductions in activity and abundance but are also
more likely to upset proteostatic mechanisms through aggregation
and proteasomal sequestration (Sato et al., 2005; McAlary et al.,
2016; Keskin et al., 2017; Farrawell et al., 2018).
Cryptic mutations
The mutations described above induce structural changes to the
SOD1 molecule that manifest as protein thermal instability,
reduced homodimer affinity, inability to correctly metalate,
reduced activity, reduced half-life in vivo and increased aggrega-
tion propensity. However, several mutations display stability and
aggregation characteristics very similar to wild-type when
observed in vitro. Shaw et al. (2010) termed these SOD1 variants
‘cryptic mutations’ because it is not clear where the source of their
toxicity lies. These include Asp90Ala, Asn86Ser, Asp101Asn,
Asn139Lys and Glu100Lys (Shaw and Valentine, 2007). Cryptic
mutations are usually surface exposed and involve the substitution
of charged residues. While we do not have experimentally derived
structures of these SOD1 mutants, analysis using the wild-type
structure as a model provides us with an indication of their effect.
In almost every case, a structural perturbation can be ascribed.
Surface mutations with mild phenotype
Asp90Ala
The Asp90Ala substitution does not affect dimer stability, metal-
ation or activity (Andersen et al., 1995; Marklund et al., 1997;
Rodriguez et al., 2002; Lindberg et al., 2005). The codon 90 posi-
tion is not well conserved and the majority of eukaryotic
CuZnSODs have a glycine residue at this site. Analysis of the
wild-type SOD1 crystal structure shows the Asp90 side-chain
making a series of hydrogen bonds within loop V with backbone
amides of Asp92, Gly93 and Val94. Substitution with alanine
would break these β-hairpin bonds but would not introduce steric
repulsion within the loop, as is the case for Gly93 mutations. As a
result, the Asp90Ala monomer is slightly destabilised (Marklund
et al., 1997; Rodriguez et al., 2002; Lindberg et al., 2005; Byström
et al., 2010). An alternative Asp90Val mutation creates further
monomer destabilisation and a more aggressive phenotype
(Morita et al., 1998; Byström et al., 2010).
Asn86Ser
The Asn86Ser mutation manifests ALS with a long disease course
and incomplete penetrance but led to an extremely severe pheno-
type in a single homozygous individual (Hayward et al., 1998;
Sato et al., 2005). Asn86 stabilises the electrostatic loop through a
hydrogen bond with Asp124 which itself hydrogen bonds with
zinc- and copper-coordinating His71 and His46. Conversion to
serine would destabilise these interactions but would not introduce
any repulsive contacts. There are no metalation studies on this
mutant and the monomer does not appear effected but the
Asn86Ser dimer is destabilised (Byström et al., 2010).
Other examples
Other charged, surface mutations which potentially fall into this
category include Glu40Gly (Bertolin et al., 2014), Asp76Tyr
(Andersen et al., 1997), Asp76Val (Segovia-Silvestre et al.,
2002), Asp11Tyr (Georgoulopoulou et al., 2010), Glu21Lys
(Jones et al., 1994a) and Glu121Gly (Canosa et al., 2015). In
each case, no bonding or Van der Walls interactions are likely
to be disturbed or the substitution could be mitigated without
changing the overall structure.
Surface mutations with typical phenotype
Asp101Asn
The Asp101Asn substitution (Jones et al., 1994b) is also structur-
ally conservative, removing only 1 Da of mass. However, it
negates the electrostatic component of a salt-bridge formed by
Asp101 and Arg79 which is conserved in more than 97% of
eukaryotic CuZnSODs. This salt-bridge forms a strong
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connection between the C-terminal end of β-strand 6 and the
upper zinc loop including spatially proximal zinc coordinating
residues His80 and Asp38. An alternative substitution for glycine
removes both electrostatic, hydrogen bonding and Van der Waals
interactions. In agreement with proposed structural changes,
Asp101Asn was shown to have stability equal to that of wild-type
in the metal-free state in vitro while Asp101Gly destabilises both
metal-free monomer and dimer states (Rodriguez et al., 2005;
Byström et al., 2010). A detailed analysis of aggregation kinetics
in HEK293 cells showed that Asp101Gly exhibits a short lag
phase before the formation of insoluble aggregates. By contrast,
Asp101Asn SOD1 initially expresses as soluble species, but fol-
lowing a long lag phase, this pool is transferred into degradation-
resistant insoluble aggregates (Prudencio et al., 2009; Ayers et al.,
2014a). Given the structure of each mutation together with their
biophysical and aggregation characteristics, it would be expected
that Asp101Gly would yield a more severe phenotype relative to
Asp101Asn. However, both mutations give rise to an early onset
and rapidly progressing form of ALS (Wang et al., 2008). A pos-
sible explanation for Asp101 mutation toxicity lies in their inabil-
ity to correctly metalate and potential weakening of the
Asp101-Arg79 salt-bridge. Ayers et al. (2014a) found that both
Asp101Asn and Asp101Gly SOD1 fail to acquire copper or zinc
in a cell-based assay. This is unsurprising given that Asp101
anchors the zinc loop to β-strand 6. Thus, like His46Arg
described in ‘Structural instability’ section, the absence of a stabil-
ity deficit in the apo state is over-shadowed by the inability of the
mutant to progress along the PTM pathway. Indeed, Asp101Asn
has also been shown to have delayed folding kinetics (Bruns and
Kopito, 2007). A second contributory mechanism may also be the
reduction of net negative charge, reviewed in ‘SOD1 net charge’
section.
ALS-associated mutations Asp101His and Asp101Try have
also been observed and would create severe clashes with Arg79,
Leu84, Val103 or Ile104 but result in a mild phenotype. Here
the combination of severe structural instability together with an
inability to metalate may create a protein that is easier to remove
through proteostatic mechanisms or sequester thereby reducing
the toxic protein load in comparison with Asp101Asn or
Asp101Gly. It should be noted however that case numbers for
the glycine, histidine and tyrosine substitutions are low making
phenotype comparisons weak.
Other examples
Other examples of surface charge mutations which lead to a typ-
ical ALS phenotype include Arg110Gly (Kostrzewa et al., 1994)
which is likely to disturb the dimer interface and hydrogen bond-
ing with loop VI helix, and Asn139Lys which is destabilised in the
metal-free state (Rodriguez et al., 2005; Münch and Bertolotti,
2010) because an internal electrostatic loop hydrogen bond is bro-
ken by the substitution. Little phenotype data are available for
Asn139Lys but SOD1 activity is reduced 46.5% (Pramatarova
et al., 1995) and given its location is likely to reduce metalation.
Like Asp101Asn described above, Asn139Lys has been shown to
have delayed folding kinetics (Bruns and Kopito, 2007).
The pathogenesis of ALS due to surface mutations
We can summarise the above sections by saying that, a substitu-
tion that perturbs the structure little, that does not affect the non-
covalent bonding configuration or does not inhibit maturation
processes, leads to incomplete disease penetrance often with
later onset or longer disease course than mean. Conversely,
large structural effects including breaking non-covalent interac-
tions, introduction of repulsive interactions or inhibition of fold-
ing or PTMs lead to high penetrance and a natural history which
is typical or comparatively severe for SOD1 ALS. As we have seen,
however, there are exceptions to this dogma. The path from struc-
ture through stability and aggregation to disease phenotype can-
not be unambiguously defined. Wang et al. (2008) found that
stability and aggregation account for only 69% of the variability
in mutant SOD1 phenotypes. There must therefore be other fac-
tors that influence disease outcomes for particular substitution
mutations.
SOD1 net charge
With a preponderance of aspartate and glutamate residues over
arginines and lysines, the SOD1 monomer carries a hypothetical
net charge of −6 at neutral pH. This is the maximum charge
found on any vertebrate SOD1 (Sandelin et al., 2007). The structure
surrounding ionisable side-chain groups together with the pH of
the subcellular locale are important determinants of protein iso-
electric point. Shi et al. (2013a) experimentally determined the
net charge on metal-free, disulphide-reduced, monomeric, wild-
type SOD1 at physiological pH to be 6.9. Formation of the
SOD1 disulphide reduces the net charge to 6.05 per monomer.
Binding of a zinc to disulphide intact SOD1 reduces the net charge
to 4.3 and further addition of copper to create fully mature SOD1
decreases the net charge further to 3.7. Thus, the SOD1 PTM path-
way increases stability but decreases monomer net charge.
ALS mutations and surface charge
ALS mutations have, on average, a propensity to reduce SOD1 net
negative charge (Sandelin et al., 2007). While 76% of negatively
charged sites have been found mutated in ALS cases, only 13%
of positively charged amino acids are known to harbour ALS
mutations, Lys3 and Arg115 only. This disparity is thought to
reflect a role of net repulsive charge in maintaining free move-
ment in the intracellular environment (Mu et al., 2017) and pre-
venting aggregation; mutation of a positive residue increases net
charge and therefore repulsion, whereas mutation of a negatively
charged amino acid decreases net charge weakening repulsion and
increasing aggregation propensity. In support of this, acetylation
of SOD1 multiple lysine side-chains with aspirin (acetylsalicylic
acid) increased fibrillation lag time and slowed growth
(Abdolvahabi et al., 2015). This could also be accomplished
with a selection of charged anhydrides which modified only a sin-
gle SOD1 lysine (Rasouli et al., 2017). In both cases, inhibition of
aggregation was not due to increased thermal stability as acylation
ubiquitously decreased SOD1 melting temperature. However,
inhibition of fibril growth was only observed in low ionic strength
buffer indicating the charge effect may be limited under physio-
logical conditions. Fibrillation inhibition also led to the accumu-
lation of SOD1 into amorphous aggregates. This may be similar to
the misfolding observed in the absence of large aggregates on cel-
lular expression of SOD1 with poorly conserved lysines mutagen-
ically removed (Crosby et al., 2018).
It is possible to fit a simple linear model of instability and sur-
vival time following disease onset by omitting outlier mutants that
change net charge. On inspection of these outliers, Byström et al.
(2010) found that net charge is a modifier of disease phenotype.
For example, Gly41Asp has a very similar relative stability and
disease onset compared with Leu106Val, but increased net charge,
and therefore repulsion, raises disease duration from 2 to 17 years.
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The converse is also apparent; reducing net charge decreases sur-
vival time with Asp101Asn as the archetype example. Metal-free
Asp101Asn stability is indistinguishable from wild-type but dis-
ease phenotype is similar to the very strongly destabilised
Ala4Val (Byström et al., 2010.)
Glu100 mutations
The case of Glu100Lys is often cited as an example where net
charge reduction leads to ALS. Glu100 is surface exposed at the
C-terminal end of β-strand 6. Its negatively charged side-chain
exists in multiple rotamers and forms no interactions with its sur-
roundings. Glu100Lys, which reduces net charge to −4, is likely to
have limited structural effects, does not reduce erythrocyte SOD1
activity, can lead to a complicated phenotype with very long progres-
sion and was shown not to co-segregate with disease in two ALS
families (Felbecker et al., 2010; Yasser et al., 2010; Keskin et al.,
2017). Conversely, the Glu100Gly mutation, which reduces SOD1
net charge only to −5, leads to a typical ALS phenotype with high
penetrance (Cudkowicz et al., 1997; Aggarwal and Nicholson,
2005; Wang et al., 2008). Glu100Gly decreases monomer stability
(Rumfeldt et al., 2006) and reduces overall thermal stability by
10 °C in the metal-free state in comparison with Glu100Lys which
only creates a 4.4 °C stability deficit (Abdolvahabi et al., 2017). A
similar relationship is also observed when initial folding is observed;
Glu100Lys acquires resistance to proteolysis only slightly slower than
wild-type, whereas Glu100Gly folding is massively reduced and it
behaves more like Ala4Val SOD1 (Bruns and Kopito, 2007).
SOD1 aggregation in ALS
Aggregation of protein is a common feature of neurodegenerative
disease and normal ageing. This is typified by the predominantly
α-synuclein-containing Lewy bodies seen in the post-mortem
substantia nigra of individuals who suffered from Parkinson’s dis-
ease. Bunina (1962) first described intracellular inclusions, later
termed Bunina bodies, surrounded by an area of clear cytoplasm
within the motor neurons of fALS cases. Single and multiple
intracellular hyaline, i.e. glassy or transparent, regions often
with Lewy body-like cores were subsequently described by
Hirano et al. (1967), also in fALS neuronal tissues. While we do
not know the content of these structures or the type of fALS
under investigation in these original cases, we do see SOD1 accu-
mulate in these structures within the cytoplasm of microglia,
astrocytes and motor neurons of mutant SOD1 transgenic animal
models and human ALS patients (Shibata et al., 1993, 1996a; Kato
et al., 1996, 1997; Bruijn et al., 1997, 1998). Together with muta-
tions in the sod1 gene, this is the central hallmark of SOD1-related
ALS. Astrocytes have been observed with their cytoplasm almost
completely replaced by 15–25 nm granule-coated fibrils. In other
glia, fibrils form non-membrane-bound inclusions but are dis-
tinctly separated from the cytoplasmic constituents (Kato et al.,
1996, 1997). The appearance of insoluble SOD1 and gliosis in
neuronal support cells appears to facilitate neuronal death
(Beers et al., 2006; Yamanaka et al., 2008). SOD1 aggregation is
also observed in Parkinson’s disease and to a lesser degree in oth-
erwise normal but aged neuronal tissue (Trist et al., 2017).
Content of aggregates
Despite the relatively high turnover of many SOD1 mutants, it is a
major component of aggregates in mutant SOD1 transgenic mice
(Jonsson et al., 2004). The SOD1 found in the amorphous and
fibrillar aggregates in the neural tissues of human and transgenic
models has been shown to be partially or completely inactive,
intra-subunit disulphide reduced, metal-free and misfolded but
full-length (Jonsson et al., 2006a; Shaw et al., 2008; Karch et al.,
2009; Bergemalm et al., 2010; Lelie et al., 2011). Wild-type
SOD1 is also present along with mutant protein and high molec-
ular mass species can be linked by abnormal disulphide bonds
(Jonsson et al., 2004; Furukawa et al., 2006; Karch et al., 2009).
Advanced glycation end products carboxymethyl-lysine, pyrraline
and pentosidine co-localise with neuronal and astrocytic inclu-
sions in human ALS and transgenic mice and are thought to be
direct SOD1 modifications (Kato et al., 1999, 2000; Shibata
et al., 1999). In mice expressing human Gly85Arg, SOD1 aggre-
gates showed ubiquitin-positive staining only at their periphery
(Bruijn et al., 1997). However, in a cell model, ubiquitin was
found to localise throughout SOD1 aggregates (Farrawell et al.,
2018). A meta-analysis performed by Ciryam et al. (2017) has
shown that five of the 15 proteins known to interact natively
with SOD1 are drawn into inclusions but the majority of the 24
proteins that are found in aggregates do not have a known meta-
bolic association with SOD1. SOD1 co-aggregators can be divided
into four broad groups which offer a snap-shot of cellular activi-
ties in response to mutant SOD1: degradation machinery,
neural-specific metabolism, neural cytoskeleton components and
chaperones including metallochaperones. This includes ubiquitin,
αB-crystalin, β-actin, metallothionine, glutamine synthetase,
tubulins, tau, S-100, Hsp-27 and 70, proteasome, vimentin, neu-
rofilament light chain, α-internexin, synaptophysin, enolase-2,
protein-disulphide isomerase, glyceraldehyde-3-phosphate dehy-
drogenase and the copper chaperone for SOD1 (hCCS) (Kato
et al., 1997, 2000, 2001b; Watanabe et al., 2001; Bergemalm
et al., 2010; Zetterström et al., 2011).
Models of aggregation
Beginning with the Gly93Ala SOD1 transgenic mice described by
Gurney et al. (1994), many strains have been produced that
express various human wild-type (Wong et al., 1995; Graffmo
et al., 2013) and SOD1 ALS mutants at different levels in different
genetic backgrounds. These include, but are not limited to,
Gly37Arg (Wong et al., 1995), Gly85Arg (Bruijn et al., 1997),
His46Arg/His48Gln (Wang et al., 2002) and Asp90Ala (Jonsson
et al., 2006b). When comparing wild-type and Gly93Ala SOD1
transgenic mice with equal transgene expression, Graffmo et al.
(2013) found mean survival time is 367 ± 56 and 155 ± 9 days,
respectively, compared to an average of 2 years for non-transgenic
mice. Thus, the toxic load of human SOD1 expression appears
cumulative in mice.
Mutant SOD1 transgenic mouse models were seen as a gold
standard test for therapy development. The most popular is the
Gly93Ala transgenic mouse created by Gurney et al. (1994), a
year after the establishment of the link between SOD1 mutants
and ALS (Rosen et al., 1993). Gurney’s mouse expresses human
mutant SOD1 at a high level, up to 24-fold that found in humans.
These mice have relatively short disease course which is conve-
nient for many types of experiment. Despite many therapeutic
approaches having been reported to positively affect
disease-related characteristics in these mice, there has been a com-
plete failure to translate these findings into new medicines
(Benatar, 2007). This has raised concern about the validity of
SOD1 transgenic mouse experiments as a whole. It remains an
open question whether the limitations arise from the transgenic
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models or the nature/protocols of the experiments and their
limitations.
To further our understanding of the aggregation process,
numerous cell and in vitro models have been developed.
Mutant SOD1 aggregations are seen in cell culture models of
ALS where they replicate some of the characteristics of post-
mortem tissues (Durham et al., 1997; Koide et al., 1998). SOD1
was first observed to aggregate in vitro in response to oxidative
modification (Rakhit et al., 2002). Light scattering at 350 nm by
SOD1 in the presence of soluble copper (II) showed that the
metal-depleted enzyme readily forms high molecular mass spe-
cies. The authors posed the question ‘do these in vitro aggregates
represent aggregates seen in ALS?’. This experiment illustrates the
difficulty of recapitulating the disease state in vitro; any protein
will aggregate if treated harshly enough, how is one to attach sig-
nificance to that given that the nature of aggregates in living neu-
ronal tissue is far from clear. Addressing this question, Lang et al.
(2015) showed a resemblance between in vitro aggregates and
those that appear in transgenic mouse models of ALS. Using anti-
body probes to characterise the surface of aggregates, they found
that solvent-exposed structures are maintained in vitro and in
mice. Similarly, with thioflavin T binding, they showed that the
dynamics of growth in both systems can be equated.
Amyloid or not?
SOD1 aggregates have been shown to bind amyloid-sensitive dyes,
such as congo red or thioflavin T and S, but yield less fluorescence
than is observed for amyloid-β or α-synuclein (DiDonato et al.,
2003; Chattopadhyay et al., 2008; Furukawa et al., 2008; Oztug
Durer et al., 2009). Thioflavin S stains inclusions formed by the
artificial SOD1 double mutant His46Arg/His48Gln and ALS
mutants Gly37Arg, Gly85Arg and Gly93Ala in transgenic
mouse spinal cord tissue (Wang et al., 2002). The form of the
fibres observed by Kato et al. (1996, 1997) seems to support the
notion of amyloid fibrillation. However, Kerman et al. (2010)
have shown that SOD1 aggregates in spinal cords are non-
amyloid. Instead they contain monomeric and unfolded SOD1
in a highly amorphous arrangement. To our knowledge, there
are no reports of SOD1 amyloid structures found in human post-
mortem ALS tissues. On the contrary, they have been shown not
to bind congo red and thioflavin S (Kato et al., 1996). This does
not mean the results of aggregation studies using thioflavin T
fluorescence as a read-out for aggregation, for example, should
be ignored. We should however expect the structure of SOD1
aggregates to differ from that of amyloid-β or α-synuclein. By
extension, the structure or affinity of the dye-aggregate complex-
ation will be altered and therefore the fluorescent properties of the
dye itself.
Aggregate structure
For SOD1 aggregates, formation dictates form. This aphorism is
true in two respects: Firstly, aggregation kinetics dictate morphol-
ogy (Abdolvahabi et al., 2016) (described in the following sec-
tion), and secondly, the regions of the SOD1 molecule that
mediate aggregation are sequestered within the aggregate struc-
ture. In the latter case, small hydrophobic side-chains occupy
the core of the proto-fibril-like structure and exclude water in a
manner reminiscent of the normal SOD1 folding nucleus
(Nordlund and Oliveberg, 2006).
Insights on the structure of SOD1 fibrils can be gained from
the observation of the immature state. In solution, wild-type
metal-free SOD1 retains only one surface of the β-barrel
(β-strands 1, 2, 3 and 6). The β-strands of the opposing face
including loops constituting both metal sites, the active site chan-
nel, the disulphide sub-loop and a sizable portion of the dimer
interface, all which are highly conserved across eukaryotic
CuZnSODs (Fig. 4b), are significantly destabilised (Banci et al.,
2009). Simulation of aggregation in silico also shows β-strands 1
and 2 self-associate to form β-sheet structures (Bille et al.,
2013). Binding of conformation-specific antibodies to segmented
epitopes along the SOD1 primary sequence confirms the presence
of β-strands 1, 2, 3 in the core of aggregates along with strand 8
(Bergh et al., 2015). β-strands 1, 2 and 6 along with strand 7
are found sequestered in aggregates as determined by protease
digestion followed by mass spectrometry assignment; however,
this varies along with mutation (Furukawa et al., 2010).
Clues as to the structure of SOD1 aggregates can be gleaned
from the ALS mutations themselves. C-terminal truncations at
positions Leu117 (with four amino acids inserted before the
stop codon), 127 (with five amino acids inserted before the stop
codon), 125, 141 and 146 (Fig. 4a) are known to cause ALS in
people and transgenic mice with intraneuronal SOD1-positive
inclusions (Jackson et al., 1997; Zu et al., 1997; Jonsson et al.,
2004; Wu et al., 2012; Nakamura et al., 2015). Thus, the electro-
static loop and β-strand 8 including Cys146 are not required for
aggregate formation.
Bergh et al. (2015) explored the variability of mutant SOD1
aggregate isoforms in transgenic mice and found that Asp90Ala
aggregates had a distinct structure, with solvent exposure of
β-strands 5, 6, 7, that was not seen in Gly93Ala, Gly85Arg and
wild-type SOD1 isoforms. β-strand 4 and the disulphide sub-loop
were however consistently found on the exterior of SOD1 aggre-
gates and in a conformationally plastic state regardless of muta-
tion. Notably, the Asp90Ala strain of SOD1 aggregation also
appears in neuronal tissues of ALS patients with mutations in
non-SOD1 genes whereas the aggregate strain common to other
SOD1 mutations was not present (Forsberg et al., 2019). The
two strains of SOD1 aggregate may represent the amorphous
and fibrillar aggregates seen in cell-free assays (Abdolvahabi
et al., 2016). Switching between deposition into each form can
be controlled with the presence of calcium or the method used
to induce aggregation (Stathopulos et al., 2003; Leal et al.,
2013). Solid-state NMR spectroscopy on fibrils formed by the
SOD1 β-barrel core, stripped of electrostatic and zinc loops, indi-
cates that β-strands 2, 3 and 5 retain their conformation from the
free state. The rest of the molecule adopts a heterogeneous struc-
ture with multiple different conformations (Banci et al., 2014).
CD spectroscopy on fibrillar metal apo-SOD1 shows that its
β-sheet content is increased with respect to soluble metalated
and metal-free SOD1 (Banci et al., 2007). Thus, some of the
unstructured strands and loops present in the free state reconfig-
ure during the fibrillation process. In cells, SOD1 aggregates
appear porous. This facilitates the diffuse movement of soluble
proteins and small molecules throughout the inclusion
(Matsumoto et al., 2005; Abdolvahabi et al., 2015). SOD1 aggre-
gates are therefore extensively β-structured, with the first three
β-strands internalised but greatly heterogeneous in both constitu-
ents and conformation when compared to classically amyloid
states (Fig. 9a).
Aggregate heterogeneity presents a problem for direct structural
study, but much has been learnt by breaking the SOD1 molecule
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down into peptides which self-assemble into fibrils amenable to
crystallographic structure determination. Using this approach, seg-
ments from C-terminal β-strand 8 (residues 147–153) and loop VI
(residues 101–107) were shown to form steric zippers through
hydrophobic side-chain interactions (Ivanova et al., 2014).
Alternatively, a peptide representing β-strand 3 (residues 28–38)
formed a twisted β-sheet structure through backbone hydrogen
bonding with the individual β-strands aligned in the direction of
polymerisation (Sangwan et al., 2017). This contrasts markedly
with information on amyloid commonly found in cross-β struc-
tures (Fig. 9b) and further explains the subdued response from tinc-
torial dyes charting SOD1 aggregation.
Aggregate formation
Cellular mechanisms exist to aid protein folding or to destroy pro-
teins which have veered irretrievably off their folding pathway.
Part of this functionality separates misfolded species into different
cellular compartments (Kaganovich et al., 2008). Intracellular
stress granule formation occurs following heat-shock. These
dynamic compartments harbour RNAs together with a collection
of proteins with RNA-binding capacity coupled with the struc-
tural disorder. ALS mutant SOD1 has a tendency to accumulate
into distinct domains around preformed stress granules with
chaperones and ubiquitin. SOD1-containing stress granules are
less dynamic than normal and can be transported along microtu-
bules to JUNQ-like aggresomes (Johnston et al., 2000; Mateju
et al., 2017). Localisation of mutant SOD1 to the JUNQ has
been demonstrated in human ALS post-mortem spinal motor
neurons and is toxic in cell models (Weisberg et al., 2012).
SOD1 aggregates form and grow in vitro following a sigmoidal
growth curve as any population does in a new environment with
limited resources (Fig. 10). Aggregation must first be initiated,
and this is marked by a lag period before a change in a parameter
such as thioflavin T fluorescence is observed. This period before
aggregation nucleation is highly variable and indicative of a sto-
chastic process. Nucleation is followed by exponential growth
which plateaus when the available substrate is exhausted (Banci
et al., 2007; Chattopadhyay et al., 2008; Abdolvahabi et al.,
2016). However, in vivo SOD1 translation can supplement avail-
able substrate and indefinitely postpone slowing of growth within
cells. In addition, a competition exists between recruitment of
substrate protomers to fibrillar or amorphous aggregates
(Fig. 10) (Abdolvahabi et al., 2016).
Aggregation is a concentration-dependent process (Hofrichter
et al., 1974) and this is clearly seen in aggregate formation
induced by variable expression levels of human wild-type and
mutant SOD1 in transgenic mice (Wong et al., 1995; Graffmo
et al., 2013). In humans, SOD1 is posited to be supersaturated
based on calculated aggregation propensity and intracellular con-
centration (Ciryam et al., 2017). The molecular environment also
plays a role, with other solutes essentially increasing the effective
concentration of SOD1 by molecular crowding thereby promot-
ing fibrillation (Ma et al., 2012). The solubility of SOD1 mutants
and the ability of the cell to reduce the prevalence of toxic spe-
cies through degradation are therefore a key. This may be
reflected in the varying aggregation propensity of different
SOD1 mutants and the lack of correlation between different
experimental systems (McAlary et al., 2016; Abdolvahabi
et al., 2017).
Fig. 9. The structure of SOD1 aggregates. (a) SOD1 β-strands in the N-terminal region of the protein are found to be structured in the metal-free state by NMR (Banci
et al., 2009). These are also commonly found to form the core of SOD1 aggregates as determined by modelling, antibody reactivity, resistance to proteolytic cleav-
age and solid-state NMR (green) while the absence of the C-terminal region in truncated forms of SOD1 negates its role in aggregation (red). (b) SOD1 β-strand 3
forms fibril structures with the alignment of each peptide parallel to the direction of strand elongation in contrast to traditional amyloid where the constituent
protein or peptide assembles perpendicular to the direction of propagation.
20 Gareth S.A. Wright et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S003358351900012X
Downloaded from https://www.cambridge.org/core. IP address: 194.66.246.18, on 25 Nov 2019 at 10:01:26, subject to the Cambridge Core terms of use, available at
Monomeric SOD1 had been implicated in the pathogenesis of
ALS (Hough et al., 2004; Rakhit et al., 2004; Ray et al., 2004)
partly in response to the first oxidation-mediated SOD1 aggrega-
tion experiments, but the toxicity of a soluble, low molecular mass
species was proven almost a decade later by Brotherton et al.
(2013). A SOD1 species existing as a monomeric, metal-free,
disulphide-reduced, globally unfolded random coil and is
enriched by SOD1 ALS-related mutations (Luchinat et al., 2014;
Lang et al., 2015). However, this completely unstructured mono-
mer must still fold into β-structure-rich fibrils. Anzai et al. (2017)
and Chattopadhyay et al. (2015) proposed a destabilised and aber-
rantly disulphide-bonded dimer as the protomer species, while
Proctor et al. (2016) found, with the aid of atomic force micros-
copy, SEC and modelling, that SOD1 forms a trimer with
non-native dimer interfaces and very substantial structural rear-
rangement. Banci et al. (2007) had previously observed this phe-
nomenon in wild-type SOD1 and we have seen it occur to
monomeric and dimeric Ala4Val SOD1 (Wright et al., 2013).
By mutagenic stabilisation of the interfaces, Proctor et al. (2016)
found they could trap this trimer on route to high molecular
mass aggregates. They also found a correlation between the stabil-
ity of the trimer and cell death. However, no single species has
been definitively demonstrated as pathogenic or to nucleate aggre-
gation, indeed each may exert toxicity, and together they form a
continuum on the path to larger aggregates.
Prion-like behaviour of SOD1
Assays of SOD1 aggregation often use mechanical agitation to
speed fibrillation by fragmenting growing fibrils thus providing
exponentially more termini for the incorporation of protomers.
Initiation of fibrillation can also occur by seeding; transfer of
wild-type or mutant fibrils from a mature reaction to a lag-phase
reaction of the same or a different SOD1 variant (Fig. 10) (Chia
et al., 2010). Importantly, transfer of spinal cord homogenate
from mutant SOD1 transgenic mice to an in vitro aggregation
reaction has the same effect, demonstrating that these assays
mimic in vivo aggregate structure and formation of kinetics.
Zil’ber et al. (1963) showed that spinal cord and medulla
oblongata homogenates from post-mortem ALS individuals
could induce ALS-like symptoms in macaque monkeys. CNS
homogenates or CSF fluid from these monkeys were also compe-
tent to induce ALS-like symptoms in other monkeys. Conversely,
transfer of homogenates from human ALS patients to non-
transgenic mice or Guinea pigs does not yield any ALS-like symp-
toms but transfer from human mutant SOD1 patients to mutant
SOD1 transgenic mice reduces survival (Zil’ber et al., 1963;
Bidhendi et al., 2018). Similarly, seeding with mouse mutant spi-
nal cord homogenate reduces the age at which ALS-like symp-
toms are first observed in a transgenic mouse recipient and
their age at the time of death (Ayers et al., 2014b; Bidhendi
et al., 2016).
Intracellular SOD1 is actively excreted into cerebrospinal fluid
where it constitutes 75% of the total SOD activity (Jacobsson
et al., 2001). In addition, misfolded SOD1 can be secreted by
motor neurons and astrocytes and can traverse the extracellular
space within exosomes (Urushitani et al., 2006; Gomes et al.,
2007). Aggregated SOD1 is also effectively imported by micropi-
nocytosis facilitating transfer from dead cells to those nearby. This
pathway facilitates the transfer of aggregated SOD1 between cells
without direct physical contact and seeds cytoplasmic accumula-
tion of mutant SOD1 in recipient cells which may not yet have
initiated aggregation (Münch et al., 2011; Grad et al., 2014).
Misfolded wild-type SOD1 can be a component of the aggregates
transferred from one cell to another, but once misfolding has been
seeded, wild-type SOD1 can continue this function without the
necessity of mutant SOD1 (Grad et al., 2014).
Transgenic mouse experiments have shown that the site of
seed inoculation largely dictates the site of initial SOD1 aggrega-
tion and the onset of disease symptoms. This is followed by the
spread of aggregates along the neuroaxis and into the brainstem
possibly across synaptic junctions (Ayers et al., 2016; Bidhendi
et al., 2016). This parallels the human ALS phenotype where
symptoms of the disease arise in a single region of the body
and spread as the disease progresses (Ravits and La Spada,
2009). Molecular and clinical characteristics of SOD1-ALS are
therefore strongly reminiscent of the prion diseases where protein
misfolding is templated and pathogenic. By implication, a single
misfolding or aggregation event is sufficient to trigger the disease
and this may account for variability in age of onset and reduced
penetrance of some SOD1 mutants. The propagated misfolding
paradigm also opens the somewhat remote possibility of
person-to-person transmission as has been observed for
amyloid-β (Jaunmuktane et al., 2015).
Impact on disease
Intuitively one would expect the molecular characteristics of
mutant SOD1 to manifest at some level in the disease phenotype
in light of the relatively simple inheritance and disease penetrance
of many SOD1 mutants. Armed with a cause and effect hypoth-
esis such as increased aggregation propensity leads to shorter dis-
ease duration (Prudencio et al., 2009), and the ability to define
this process in vitro or in cells, how good are we at predicting
the disease? Lindberg et al. (2002) first related the stability of
mutant, immature SOD1 to patient survival time after initial diag-
nosis. Wang et al. (2008) developed this using the Chiti–Dobson
equation and found that 69% of the variability in disease duration
could be accounted for by the synergistic effect of mutant SOD1
instability and aggregation. This was subsequently disputed in
light of DSC and dynamic light-scattering characterisation of sev-
eral SOD1 mutants (Vassall et al., 2011). Given the stochasticity
Fig. 10. SOD1 aggregate growth. SOD1 fibril growth is commonly assayed in vitro
using a fluorescent dye such as thioflavin T. Fibril growth is preceded by a lag
phase where little aggregation takes place. Aggregation is then nucleated in a sto-
chastic process leading to exponential growth. Growth plateaus when all available
SOD1 has been incorporated into aggregates. Each process can be modified by
changing the SOD1 mutant under investigation, its concentration, adding aggregate
seeds or sequestering protein in non-fibrillar aggregates.
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in relatively simple microplate fluorescence assays for SOD1
aggregation (Abdolvahabi et al., 2016), the small sample sizes of
each SOD1 ALS mutation together with human genetic, physical
and environmental heterogeneity, and the inherent differences in
SOD1 mutations themselves sometimes resulting in incomplete
penetrance, it will always be difficult to predict clinical milestones.
In an effort to combat the latter point, a small angle X-scattering
study focussed only on ALS substitutions at the Gly93 site was
able to discern differences in their aggregation paralleling disease
course following diagnosis (Pratt et al., 2014). A second option is
to increase the number of data points and restrict experimental
conditions by looking at the relationship between in vitro and
cell or transgenic models. Lang et al. (2015) showed a good
inverse linear relationship between mutant transgenic mouse sur-
vival times and the ratio of unfolded aggregation precursor to
total SOD1 protein. A similar effect was seen in cultured neuronal
cells (McAlary et al., 2016).
Are aggregates toxic?
By benchmarking our model systems against the disease, it should
be possible to find entities that inhibit disease characteristics in
the model system and then apply that knowledge to the disease
in humans. This philosophy only functions if we study the toxic
species. Aggregates clearly co-segregate with SOD1 mutations
and by extension SOD1-related ALS. Furthermore, their presence
augurs rapid cell death (Matsumoto et al., 2005). However, true
insoluble aggregates only appear at late stages in transgenic
mouse models, after or disconnected from the onset of ALS-like
symptoms, indicating they may be a response to toxicity or innoc-
uous bi-product rather than a cause. Highlighting this point, Gill
et al. (2019) found that the amount of aggregated SOD1 in trans-
genic mouse spinal cord was inversely proportional to disease
progression as measured by NeuroScore. Thus, mice fair better
if they sequester more SOD1 in aggregates. The authors also
found that regions most affected by disease displayed higher solu-
ble misfolded to total soluble SOD1 ratios (Gill et al., 2019). These
low molecular mass, soluble misfolded SOD1 species, free of all
PTMs are present throughout life (Jonsson et al., 2004; Rakhit
et al., 2007; Zetterström et al., 2007; Lee et al., 2015; Gill et al.,
2019) and may therefore be a better candidate for the toxic species
than inert aggregates.
Mitochondrial toxicity
The pathway from SOD1 mutations to destabilisation, misfolding
and aggregation is well delineated. This does not however, tell us
why neuronal cells die in SOD1 ALS. Accumulation of ubiquiti-
nated SOD1 into aggregates which also sequester chaperone pro-
teins is a potential source of toxicity as proteostatic activities
become impaired. Another possible source of toxicity is the
degeneration of mitochondria.
Transgenic mice expressing Gly37Arg human SOD1 develop
intraneuronal vacuoles that displace cytoskeletal structures. The
vacuoles appear to be mitochondria with intermembrane spaces
swollen to the point of membrane structure breakdown (Wong
et al., 1995). Vacuolisation appears in the presymptomatic stage
and increases in prevalence as disease symptoms manifest and
progress but their occurrence is largely restricted to axons and
dendrites (Kong and Xu, 1998). SOD1 transported into the mito-
chondrial IMS in the disulphide-reduced, metal-free state and is
retained through hCCS-catalysed maturation. Mutant and wild-
type SOD1 aggregate within mitochondria (Pasinelli et al., 2004;
Vijayvergiya et al., 2005; Deng et al., 2006; Cozzolino et al.,
2009) leading to membrane disruption (Oladzad Abbasabadi
et al., 2013; Salehi et al., 2015; Watanabe et al., 2016).
Progressive vacuolisation may be a consequence of this aberrant
accumulation. The combined effect of these changes is defective
respiration, electron transport and ATP synthesis (Bowling
et al., 2006; Magrané et al., 2012).
Membrane association
Misfolded SOD1 is found at high levels around vacuoles in trans-
genic mouse neurons in what appears to remain of the IMS
(Wong et al., 1995; Jaarsma et al., 2001; Graffmo et al., 2013).
SOD1 associates with the intracellular face of the plasma mem-
brane but misfolded SOD1 is also found on the outer mitochon-
drial membrane in ALS spinal cord cells (Petkau and Copps,
1979; Vande Velde et al., 2008). Accumulation is progressive
and, importantly, begins just prior to the onset of ALS (Pickles
et al., 2013). SOD1, particularly the metal-free state, incorporates
within biological membranes and disorders lipid packing (Petkau
and Chelack, 1976; Petkau and Copps, 1979; Lepock et al., 1981).
Chng and Strange (2014) used molecular dynamics simulations to
show how residues in the conformationally dynamic electrostatic
and zinc-binding loops bind octanol and mediate interactions
with bilayer surfaces. A C-terminal SOD1 truncation at Leu126
facilitates the adoption of a membrane-penetrant helical structure
with several transmembrane helices (Lim et al., 2015), and simi-
larly, Ala4Val SOD1 self-association created a tetramer capable
of functioning as an integral membrane ion channel (Allen
et al., 2012a).
Association of metal-free wild-type with mono- or polyunsat-
urated fatty acids including arachidonic, oleic and linoleic acid
cause SOD1 aggregation (Kim et al., 2005). When incubated
with phospholipids, Rasouli et al. (2018) found SOD1 aggregation
was influenced by the charge of the head group, lipid concentra-
tion and the SOD1 variant. For example, anionic phospholipids
greatly stimulated metal-free wild-type SOD1 fibril formation
over a broad range of concentrations whereas zwitterionic did
not. Cationic phospholipids did catalyse SOD1 aggregation but
over a much smaller range of concentration than anionic lipids.
Thioflavin T binding indicated that His46Arg did not form fibrils
and unusually Ala4Val also had limited fibrillation but wild-type,
Gly37arg and Asp90Ala did.
Like hCCS, macrophage inhibitory factor (MIF) has a direct
and high affinity interaction with both immature wild-type and
mutant SOD1 (Israelson et al., 2015; Shvil et al., 2018). MIF
inhibits SOD1 deposition onto the outer mitochondrial mem-
brane and chaperones SOD1 away from misfolding within cells
and in a cell-free environment (Israelson et al., 2015). MIF over-
expression in neuronal cells increases viability while MIF knock-
out hastens disease onset and death in SOD1 mutant transgenic
mice. MIF has low abundance within motor neurons when com-
pared with other cell types, thus this offers a rationale for motor
neuron-selective toxicity despite ubiquitous SOD1 expression.
Secondary SOD1 post-translational modifications
Four PTMs contribute to the stability and function of SOD1. They
are, in the sequential order in which they likely occur in the cyto-
sol: zinc and copper acquisition, intra-subunit disulphide bond
formation and dimerisation. However, SOD1 is also known to
undergo a comprehensive range of secondary PTMs that are
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not necessary for the formation of the functional dimeric mole-
cule (Fig. 11). These non-inheritable modifications can change
the chemical and biophysical properties of SOD1 as do
ALS-related mutations and so may have implications for the path-
ogenesis or treatment of ALS. Here we review only those PTMs
that have an association with ALS.
Acetylation
Like many human proteins, the SOD1 N-terminus is cleaved to
form acetylalanine (Barra et al., 1980; Jabusch et al., 1980).
Covalent addition of an acetyl group can also take place at acces-
sible serine or lysine residues and changes the overall surface
charge of a protein. Lysine acetylation is a global regulator of pro-
tein activity and signalling. SOD1 Lys70, which is solvent exposed
on the surface of the zinc-binding loop, has been observed to be
acetylated in cell culture and reduces the amount of soluble SOD1
in a manner similar to ALS mutations. Addition of deacetylase
inhibitors increased the prevalence of this modification and
decreased SOD1 activity by inhibiting hCCS-dependent activa-
tion. Sirtuin-1 is known to act as a deacetylase for SOD1 Lys70
and restores activation by hCCS (Lin et al., 2015). Acetylation
of Lys122, on the N-terminus of the electrostatic loop, does not
change SOD1 activity but is found only in specific cell types
and regions within the CNS indicating functional importance
(Kaliszewski et al., 2016). Non-specific lysine acetylation of wild-
type, Asp90Ala and Ala4Val SOD1 with aspirin in vitro inhibited
the nucleation rate and extension of aggregates overall. As the
number of acetyl groups increased, the thermal stability of metal-
free SOD1 decreased. Destabilisation of acetylated fibril aggregates
was also observed and thought to occur by Coulombic repulsion
(Abdolvahabi et al., 2015).
Glycation
Protein glycation is the irreversible, stochastic, non-enzymatic
addition of a sugar or dicarbonyl to protein amino groups. In
practice, addition is usually limited to arginine and lysine side
chains. Initial addition is followed by a series of reactions which
lead to heterogeneous advanced glycation end-product (AGE)
formation. AGEs negatively affect proteins by inhibiting function,
crosslinking, decreasing solubility and increasing protease resis-
tance. As a result, they are associated with neurodegenerative dis-
eases such as Alzheimer’s and Parkinson’s diseases (Li et al.,
2012). Arai et al. (1987a) found glucose-modified SOD1 to con-
stitute roughly 20% of the erythrocytic SOD1 pool and also
found differences in glucosylation between SOD1 from young
and old cells. In vitro glucosylation occurs at Lys3, Lys9, Lys30,
Lys36, Lys122 and Lys128. These modifications reduce SOD1
activity (Arai et al., 1987a, 1987b). Modification of metalated
and metal-free wild-type SOD1 with the advanced glycation end-
product precursor methylglyoxal induces partial unfolding and, in
the case of apoSOD1, the formation of high molecular mass olig-
omers (Sirangelo et al., 2016). In addition, ALS SOD1 mutant
proteins are more easily glucosylated and fructosylated in vitro
with respect to wild-type (Takamiya et al., 2003). These in vitro
experiments are of importance because AGE-modified SOD1 is
a major component of aggregates found in post-mortem ALS
neural tissues (Kato et al., 1999, 2000; Shibata et al., 1999).
Oxidation
Oxidative stress has long been associated with neurodegenerative
disease and ALS is a typical example. SOD1 was first observed to
aggregate in response to oxidative damage by Rakhit et al. (2002).
Oxidation of wild-type SOD1 by hydrogen peroxide causes
Fig. 11. Secondary post-translational modifications and drug molecule interactions with human SOD1. Post-translational modifications observed ex vivo or in vitro are
listed along with several structures of drug molecule interactions which have been validated crystallographically at Trp32 and Cys111 sites. Cysteinylation of Cys111
is the only native SOD1 post-translational modification which has been crystallographically characterised and was found to be destabilising (Auclair et al., 2013a,
2013b).
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misfolding and aggregation in vitro and in cells. Furthermore, oxi-
dation promotes association with ubiquitin and Hsp70, as is the
case in human mutant SOD1 aggregates, and is toxic to motor neu-
ron cultures (Ezzi et al., 2007). There are three sites at which SOD1
is known to be oxidised: Cys111, Trp32 and the copper site histi-
dines. Efficient formation oxo-histidine-118 bovine SOD1 (His120
human numbering) by hydrogen peroxide has been observed in
vitro (Uchida and Kawakishi, 1994). Multiple human SOD1 copper
site histidines are oxidised by ascorbic acid-CuCl2, again in vitro
(Rakhit et al., 2002). There is no evidence of copper site modifica-
tion in the cellular environment or an impact on ALS but Cys111
and Trp32 both have implications for disease pathogenesis.
Human SOD1 Cys111 residues are solvent exposed but oppose
each other 9 Å apart across the sub-unit interface when the pro-
tein is in the dimeric form. Their side-chain sulphydryl groups are
reactive (Calabrese et al., 1975). Cysteine is used sparingly in
nature due to its reactivity and a cysteine at position 111 is
uncommon in the primary sequence of SOD1 orthologues. Its
persistence in different phylogenetic groups however could
point to a functional role, possibly environmental redox sensing
(Go et al., 2015). Cys111 is known to be a key modulator of
SOD1 expression level, folding, stability, aggregation and toxicity
(Jabusch et al., 1980; Lepock et al., 1990; Hallewell et al., 1991;
Suzuki et al., 2011; Chen et al., 2012; Zhang et al., 2017). A poten-
tial mechanism for this may be found in the asymmetry and
hydrogen bonding network of SOD1 loop VI within which
Cys111 is found (Ihara et al., 2012). The Cys111 side-chain
sulphydryl is amenable to a host of post-translational modifica-
tion reactions, the simplest of which is reversible oxidation to sul-
phenic acid (Xu et al., 2018). Successive addition of oxygen by
hydrogen peroxide or incubation in the air creates sulphinylated
and sulphonylated SOD1. Sulphonylation of wild-type SOD1
Cys111 predisposes it to adopt a Gly93Ala mutant-like conforma-
tion and inhibits fast axonal transport (Bosco et al., 2010). The
sulphonylated form increases in prevalence as the disease pro-
gresses and it also localises to hyaline inclusions found within spi-
nal cord neurons of mutant SOD1 transgenic mice (Fujiwara
et al., 2007; Chen et al., 2012; Xu et al., 2018). Finally, Bosco
et al. (2010) observed immunoreactivity of a conformation-
specific antibody which recognises sulphonylated wild-type
SOD1 in four of nine sporadic ALS cases tested but not in control
individuals or ALS cases with mutations in other genes. This
highlights the potentially disastrous effect of irreversible oxidation
on SOD1 behaviour.
Mass spectrometry analysis of erythrocytic SOD1 from
Gly93Ala and wild-type transgenic mice together with native
human wild-type SOD1 showed Trp32 to be post-translationally
oxidised (Taylor et al., 2007). Like Cys111, the presence of tryp-
tophan in the mid-point of β-strand 3, where it is unusually sol-
vent exposed for a large non-polar amino acid, is uncommon and
again suggests some functional importance. In vitro Trp32 is oxi-
dised by hydrogen peroxide in the presence of bicarbonate to
N-formylkynurenine and kynurenine or a di-tryptophan species.
This promotes misfolding and non-disulphide, covalently linked
dimerisation ultimately leading to aggregation (Zhang et al.,
2003, 2004; Medinas et al., 2010; Coelho et al., 2014). Trp32
also facilitates the conversion of wild-type SOD1 to a misfolded
form by mutant SOD1; a process which is hindered by the substi-
tution of serine at position 32 (Grad et al., 2011). Similarly, sub-
stitution of phenylalanine inhibits SOD1 aggregation and
prolongs survival of SOD1 mutant cultured neurons (Zhang
et al., 2003; Taylor et al., 2007).
Thiolation
S-thiolation is the reversible formation of mixed disulphide bonds
between free protein sulphydryls and low molecular mass cellular
thiols such as glutathione or cysteine. These modifications are
known to protect cysteine from irreversible oxidation to sulphi-
nate and sulphonate. Modification of SOD1 with cysteine or glu-
tathione results in addition to at most one Cys111 per dimer likely
due to lack of space in the inter-dimer groove (Wilcox et al., 2009;
Auclair et al., 2013a). The preponderance of glutathionylation ver-
sus cysteinylation in vivo has been disputed. Furthermore, sample
preparation under oxidative conditions has been shown to increase
the extent of thiolation (Auclair et al., 2014). S-glutathionylation
can be spontaneous or glutathione-S-transferase catalysed and
often results from oxidative stress. Covalent linkage of glutathione
to SOD1 was first observed in human erythrocyte SOD1 with the
Asp90Ala mutation (Marklund et al., 1997). The site of glutathione
adduct formation was subsequently found to be Cys111 (Wilcox
et al., 2009). Glutathionylation of mutant and wild-type SOD1
reduces dimer affinity (Redler et al., 2011; McAlary et al., 2013).
Analysing wild-type SOD1 purified from nerve tissue Auclair
et al., 2013b found roughly 40% to be cysteinylated at Cys111 in
comparison with little cysteinylation in red blood cell SOD1
(Auclair et al., 2014). This modification protected Cys111 from sul-
phinylation and sulphonylation in response to hydrogen peroxide
but decreased the protein’s overall thermal stability by 5 °C
(Auclair et al., 2013a, 2013b).
Acylation
S-acylation is the addition of a lipid group to a protein cysteine.
Palmitoylation is the most common S-acylation and involves the
catalysed formation of a covalent but reversible thioester bond
between a free sulphydryl and the fatty acid palmitate. As a result,
the hydrophobicity of the target protein is increased and this can
facilitate partitioning of otherwise soluble proteins with lipid
membranes. Disulphide-reduced SOD1 has been shown to be pal-
mitoylated in cells, transgenic spinal cord lysate and human spi-
nal cord. Modification takes place primarily at Cys6 but to a lesser
extent at Cys111 and even Cys57 and Cys146. SOD1 mutants
were also shown to have a higher degree of palmitoylation
which may be a consequence of their propensity to exist in the
disulphide-reduced state. In addition, wild-type SOD1 also
showed a higher degree of palmitoylation in sporadic ALS cases.
The degree of palmitoylation correlated with the amount of
SOD1 associated with cell membranes (Antinone et al., 2013,
2017). Further analysis found hCCS to be palmitoylated in the
opposite manner to SOD1 with decreasing levels in mutant
SOD1-related ALS and sporadic ALS (Antinone et al., 2017).
Reversible palmitoylation could therefore play a role in reducing
the three-dimensional search space of hCCS for zinc-bound,
disulphide-reduced SOD1 by facilitating membrane association
prior to copper and disulphide transfer.
Phosphorylation
SOD1 was first observed to be phosphorylated in myeloid cells
after exposure to granulocyte-colony stimulating factor (Csar
et al., 2001). It has subsequently been shown to be phosphorylated
at Thr2, Ser59 and Ser98 (Wilcox et al., 2009; Tsang et al., 2014).
Ser59 and Ser98 are phosphorylated through a direct interaction
with Dun1 in response to oxidative stress and this directs SOD1
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to the nucleus where it acts as a transcription factor for genes
involved in the oxidative stress response (Tsang et al., 2014).
While production of phosphorylated SOD1 in amounts necessary
for biophysical characterisation is challenging, Fay et al. (2016)
constructed and crystallised a SOD1 Thr2Asp phosphomimetic
mutant. The wild-type SOD1 structure is maintained by the
Thr2Asp substitution but strengthens the dimer interaction and
slows dissociation rates even when the Ala4Val mutation was pre-
sent along with glutathionylation at Cys111. In addition, the
authors predicted that Thr2Asp destabilises a non-native trimeric
structure. As a result, the Thr2Asp substitution reduces cell death
resulting from Ala4Val SOD1 expression (Fay et al., 2016).
Deamidation
Deamidation is the removal of the side-chain amide from a gluta-
mine or asparagine residue. Under physiological conditions, the
reaction is not enzymatic but slow and may act as a molecular
clock (Robinson and Robinson, 2001). The sequential mechanism
leads to a mixture of aspartic and isoaspartic acids. Deamidation
therefore recapitulates a single amino acid missense mutation.
SOD1 deamidation has been observed in erythrocytic SOD1
and occurs naturally to a SOD1 truncation comprising
β-strands 1–4 and the disulphide sub-loop (amino acids 1–61
incorporating Cys6/57Ser mutations) in vitro during protein puri-
fication at Asn26 (Shi et al., 2013b; Bierczyńska-Krzysik et al.,
2014). Asn26 is positioned in SOD1 loop II within a tripeptide,
Ser-Asn-Gly, known to predispose the central residue to deamida-
tion (Wright, 1991). Furthermore, single and compound deami-
dation replicating Asn/Asp amino acid substitutions created
modest reductions in SOD1 thermal stability and increased rate
of aggregation (Shi et al., 2013b).
Targeting the SOD1 molecule for therapeutic benefit
Small molecules
Small molecules, produced synthetically or derived from natural
sources, formed the mainstay of a revolution in drug discovery
that occurred in the latter half of the 20th century and still consti-
tute roughly ¾ of new chemical entities registered by the US Food
& Drug Administration. Like ALS mutations or natural amino
acid modifications, interactions with exogenous small molecules
could have positive or negative effects on SOD1 behaviours asso-
ciated with ALS. Several small-molecule strategies have been
developed to address the underlying folding, metalation, stability
and aggregation characteristics associated with ALS mutant SOD1
and target-specific sites on the SOD1 molecule.
The Trp32 site
Human SOD1 has a solvent-exposed tryptophan residue on the
surface of β-strand 3. This residue is poorly conserved with thre-
onine, serine, asparagine, glutamate, lysine and arginine all pre-
ferred across other eukaryotic CuZnSOD analogues. Indeed,
only a few simian species and the African elephant are known
to incorporate tryptophan at this position while a conservative
phenylalanine substitution is found at the equivalent position in
human extracellular CuZnSOD (SOD3) indicating hydrophobic-
ity at this site has some functionality. Accordingly, Pokrishevsky
et al. (2018) showed that substitution of Trp32 for the more fre-
quently found serine decreases mutant and wild-type SOD1
stability and resistance to proteolytic digestion.
Despite reduced stability, the Trp32Ser substitution confers a
protective effect on SOD1 aggregation. This includes slowed
aggregation kinetics, an inability to propagate Trp32 SOD1 seeded
aggregation, and a propensity to form amorphous rather than
fibrillar aggregates (Grad et al., 2011; Pokrishevsky et al., 2018).
β-strand 3 has been found in the core of SOD1 aggregates
(Bergh et al., 2015) so removing a hydrophobic interface may hin-
der fibril formation. All likely contribute to reduced loss of motor
function on the expression of Trp32Ser human SOD1 in zebra
fish in comparison with human wild-type (DuVal et al., 2019).
Thus, inhibiting abnormal SOD1 self-interactions at Trp32 is a
possible strategy to prevent aggregation and toxicity.
Several small molecules have been shown crystallographically
to bind at or near the Trp32 site. This includes a series of aromat-
ics which exploit a hydrophobic interaction with the Trp32 indole
ring system (Fig. 11) (Antonyuk et al., 2010; Kershaw et al., 2013;
Ramu et al., 2018) and four catecholamines that interact with a
groove in the SOD1 surface created by loop II close to Trp32
(Wright et al., 2013). A fragment-linking approach created one
compound which was able to bind the Trp32-loop II site with
low micromolar affinity and inhibit Trp32 oxidation (Manjula
et al., 2018), a post-translational modification known to facilitate
aggregation (Taylor et al., 2007).
5-Fluorouridine was also shown crystallographically to interact
with the SOD1 Trp32 site (Fig. 11) (Wright et al., 2013). Inclusion
of 5-fluorouridine in cell culture media prior to exposure to
human SOD1-ALS spinal cord homogenates could significantly
reduce induced SOD1 aggregation (Pokrishevsky et al., 2017).
5-Fluorouridine, uridine and telbivudine have also been shown
to have positive effects in cell and animal model systems including
postponing disease onset and increasing survival in Gly93Ala
transgenic mice (Pokrishevsky et al., 2018; DuVal et al., 2019;
Rando et al., 2019).
The Cys111 site
Like Trp32, SOD1 Cys111 is poorly conserved and oxidation of its
sulphydryl has a role in aggregation (Chen et al., 2012; Xu et al.,
2018). Opposing Cys111 residues are separated by a short distance
across the SOD1 dimer interface. Covalent tethering of Cys111
side-chain sulphydryls by maleimide cross-linking was shown to
substantially increase mutant SOD1 thermal stability (Auclair
et al., 2010). This experiment is reminiscent of covalent tethering
of the SOD1 dimers by the introduction of a Val148Cys substitu-
tion performed by Ray et al. (2004) which, taking cues from lyso-
zyme and thymidylate synthase research, was able to reinforce
Ala4Val SOD1 dimer affinity and prevent in vitro aggregation.
We were able to mimic these effects by binding the small, antiox-
idant molecule ebselen to opposing Cys111 residues where they
increased dimer affinity of Ala4Val SOD1 nearly 60-fold. In a sec-
ond mode of action, ebselen was also an efficient catalyst for
SOD1 disulphide bond formation which restored normal folding
to Ala4Val and Gly93Ala mutants within cells (Capper et al.,
2018).
Cisplatin addition to Cys111 prevents and even reverses aggre-
gation of metal-free SOD1 in cell-free and cell-based models. The
affinity of this interaction was found to be 37 µM and cisplatin
was able to increase metal-free SOD1 thermal stability by 8 °C
(Banci et al., 2012b). Crystallographic determination of the
SOD1-cisplatin structure shows the ligand positioned at Cys111
(Fig. 11) but full ligand occupancy is not possible due to steric
clashes across the dimer interface and cisplatin geometry is signif-
icantly distorted (Banci et al., 2012b; Shabalin et al., 2015).
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Metal-coordinating sites
An inability to correctly metalate is a recurring characteristic of
SOD1 mutants and increasing the availability of zinc, copper or
both is a logical response. High doses of zinc are toxic to
Gly93Ala transgenic mice but doses up to 60 mg kg−1 day−1
were tolerated. A higher dose of 90 mg kg−1 day−1 was also toler-
ated when supplemented with 0.3 mg kg−1 day−1 copper. In each
case, mouse survival was increased by roughly 10 days on average
(Ermilova et al., 2005). A subsequent 2011 ALS clinical trial
assessed a similar mixture of zinc and copper in humans for tox-
icity but details of progression beyond phase I/II are sparse.
Taking the alternative approach of increasing copper availabil-
ity, diacetylbis(N(4)-methylthiosemicarbazonato) copper (II)
(CuATSM) was shown to increase survival in Gly93Ala,
Gly37Arg and Gly93Ala/hCCS overexpressing transgenic mice
in a dose-dependent fashion (Soon et al., 2011; McAllum et al.,
2013; Williams et al., 2016; Vieira et al., 2017). In a cell model,
CuATSM increases SOD1 abundance and activity while reducing
aggregation and cell death but only for non-metal-binding site
mutants (Farrawell et al., 2019). CuATSM has recently completed
a phase I clinical trials with a further phase I dose escalation trial
underway and a phase II trial began on 30 September with com-
pletion date of 30 December 2020.
Promoting production of stable SOD1 over unfolded or aggre-
gated species with pharmaceutical chaperones has been one of the
two most explored avenues for SOD1-specific therapeutic devel-
opment. What holds these strategies back as effective treatments
for SOD1 ALS are combinations of toxicity, specificity, affinity
and delivery; problems often associated with drug discovery but
especially difficult to overcome when the target is in the central
nervous system.
Biologics
Biologics, including antibodies and engineered proteins, offer a
solution to the specificity problem above. The SOD1 interactome
is relatively small but several interaction partners have the poten-
tial for therapeutic repurposing. This repertoire has been broad-
ened by surface display techniques, directed evolution and novel
antibody generation providing us with many proteins which are
able to specifically interact with disulphide-reduced, metal-free,
aggregated or soluble misfolded SOD1.
Antibodies
The production of antibodies which react specifically with SOD1
structural conformations commonly found in ALS has revolution-
ised our understanding of the SOD1 structure–misfunction rela-
tionship in the last decade or so. These antibodies are often
termed misfolding-specific because they preferentially bind epi-
topes that are not accessible when SOD1 is mature, either through
internalisation or reduced conformational dynamics. The first
such antibody was a polyclonal generated against a peptide
found in β-strand 8 including the disulphide-forming Cys146
and specifically recognised monomeric SOD1 (Rakhit et al.,
2007). Together with analytical or diagnostic use, conformation
or mutant-specific antibodies may also have therapeutic applica-
tions. While SOD1 aggregates are found within cells, there is
strong evidence that aggregates or small misfolded species can
traverse the extracellular space and seed aggregation in surround-
ing cells. If this toxic transport could be inhibited, the progressive
nature of ALS could be arrested. Justification for this comes in
part from work showing the presence of native SOD1 reactive
antibodies in sporadic ALS sufferers with longer than mean sur-
vival (van Blitterswijk et al., 2011).
The D3H5 IgG antibody was generated against recombinant,
metal-free Gly93Ala SOD1 and when delivered directly to the
cerebral ventricles was able to postpone weight loss and increase
life span by small amounts. Increasing the period over which
the antibody was administered and starting the treatment earlier
increased survival from +6 to +9 days compared to control
Gly93Ala transgenic mice (Gros-Louis et al., 2010).
Active immunisation with peptides designed to create a native
immunogenic response specific for misfolded SOD1 has also been
shown to increase life-span and slow disease progression in trans-
genic mice (Urushitani et al., 2007; Liu et al., 2012). However,
selection of the immunising peptide has to be carefully considered
to not induce an immune response which in itself can be life
threatening (Sábado et al., 2015).
Single-chain recognition proteins
High-affinity antibodies can now be generated through traditional
protocols cheaply and efficiently. However, their size, flexibility
and quaternary structure present a problem for structural study,
rational redesign and intracellular delivery. Single-chain recogni-
tion domains circumvent these problems and have found interest-
ing uses in relation to SOD1.
Patents have been filed for SOD1-reactive nanobodies; small,
single-chain antibodies often generated by immunisation of cam-
elids. Micro-nanomolar binding affinity for wild-type and mutant
SOD1 has been described which was able to prevent the forma-
tion of large Ala4Val SOD1 fibrils in vitro with some protein
forming small amorphous aggregates. Expression of the nanobody
within cells reduced SOD1 aggregation and a single direct delivery
of nanobody to Gly93Ala SOD1 transgenic mouse brain delayed
disease onset and prolonged survival (Robberecht et al., 2016).
A thermophilic variant of the immunoglobin-binding protein
G B1 domain (HTB1) was optimised for SOD1 binding by direct-
ing mutations to putative stable regions on the surface of the pro-
tein followed by yeast surface display (Banerjee et al., 2017).
Unmodified HTB1 could not bind SOD1 while the product of
this process was a binding domain with 300 and 674 nM dissoci-
ation constants for Gly93Ala and Gly37Arg, respectively. In vitro
aggregation in the presence of modified HTB1 showed SOD1
forming small amorphous aggregates rather than large fibrils,
reduced intracellular SOD1 misfolding and increased cell viability.
The versatility of this technique is illustrated by the successful
retargeting of HTB1 to bind amyloid-β peptide with low micro-
molar affinity with positive effects on aggregation and toxicity
(Banerjee et al., 2018).
Using phage display in bacteria, Ghadge et al. (2013) created
two single chain variable fragments (scFv) from a pre-existing
library which were able to interact with wild-type, Ala4Val and
Val148Gly SOD1 but not Gly93Ala SOD1 possibly indicating
Gly93 forms part of the protein–protein interface. When
co-expressed with Ala4Val SOD1 in neuronal-like cells, SOD1
aggregation was reduced and cell viability was increased.
Ghadge et al. (2018) then showed that scFV adeno-associated
viral (AAV) delivery to Gly93Ala transgenic mice increased sur-
vival when administered neonatally and just prior to the onset
of symptoms. On the whole, single chain recognition domains
do not replicate the very high target affinity that can be found
with well-selected antibodies. However, when combined with reli-
able, efficient and targeted gene delivery by AAV vectors, these
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small proteins are a very promising new strategy to engage and
change the fate of many cellular proteins including SOD1.
Conclusion
After more than 50 years of concerted effort, we have gained a
very detailed understanding of SOD1 biology. Despite this body
of work, new SOD1 functions and behaviour are regularly discov-
ered including, in recent years, a role in signalling, stress granule
formation and transcriptional regulation. Perhaps the most enig-
matic behaviour of SOD1 discovered over these years is its pro-
pensity to aggregate and the ramifications this has on ALS.
We now understand how ALS mutations cause aggregation in
SOD1-ALS. Generally, mutations to conserved residues in the
metal-binding, disulphide, dimer interface half of the SOD1
β-barrel prevent adequate folding and acquisition of a stable
structure. These unfolded structures predispose mutant SOD1
to degradation but also lead to the accumulation of the non-
conserved part of the barrel into non-amyloid fibrils or amor-
phous aggregates. While the exact structure of these aggregates
remains unresolved, the research community is developing the
tools with which to arrest their formation. Small-molecule thera-
pies including CuATSM and ebselen confer order on the func-
tional part of the SOD1 β-barrel while Trp32-targeting
compounds bind in the region known to form the core of
SOD1 aggregates. What currently limits the usefulness of these
compounds as therapeutics, either singly or as a cocktail, is a com-
bination of affinity, specificity and delivery. Honing delivery of
zinc and copper, the specificity of disulphide formation and the
affinity of anti-aggregation compounds will be necessary for this
strategy to succeed in the clinic.
The presence of SOD1 aggregates in mutant SOD1 cases of
ALS is unquestionable but there is also strong evidence that wild-
type SOD1 is a component of aggregates in at least some sporadic
ALS cases (Shibata et al., 1994, 1996b). There are also many
reports of misfolded SOD1 in sporadic ALS cases (Bosco et al.,
2010; Forsberg et al., 2010; Pokrishevsky et al., 2012; Grad
et al., 2014; Paré et al., 2018). Some of the secondary post-
translational modifications described in ‘Secondary SOD1 post-
translational modifications’ section may be responsible for desta-
bilising wild-type SOD1 and lead to misfolding (Bosco et al.,
2010). This topic is however contentious; Da Cruz et al. (2017)
found no SOD1 misfolding in sporadic ALS samples. If differ-
ences in detection are eliminated, this discrepancy must arise
from the tissue source, inherent variability of patient samples
and subjective data interpretation.
Heterogeneity is common in ALS and we should not be sur-
prised that some sporadic cases, or tissues therein, exhibit
SOD1 misfolding and aggregation while others do not. The size
of aggregates, the abundance of misfolded SOD1 and the propor-
tion of cells that display these characteristics is also key here.
Discovery of misfolded SOD1 in non-SOD1 fALS cases,
Parkinson’s disease and aged but healthy individuals supports
the notion that SOD1 aggregates are a commonality in ageing
and neurodegenerative disease (Nishiyama et al., 1995; Trist
et al., 2017; Forsberg et al., 2019). In each case, the size and num-
ber of these inclusions was lower than is common in SOD1-ALS
patients, thus it may be that investigators expect to see large
mutant SOD1-like aggregates when much smaller, punctate
forms are missed in non-SOD1 ALS tissue samples.
If SOD1 aggregation is common to mutant SOD1-ALS,
non-SOD1 ALS, neurodegenerative disease in general and ageing,
is it toxic? The toxicity of protein or peptide aggregates has been
questioned recently across neurodegenerative disease research.
Low molecular mass misfolded species including SOD1 trimers
with non-native secondary, tertiary and quaternary structure
have been posited to be toxic (Zhu et al., 2018). These species
may exist within cells but there is currently no clear rationale or
mechanistic understanding as to their toxicity. Basic science
examining this concept is of the upmost importance if we are
to create new, viable therapeutics to specifically address these
species.
The linkage of SOD1 with ALS in 1993 stimulated a prolifer-
ation in research and understanding of SOD1 biology.
Throughout, biophysics has been at the forefront, and as we
find answers to the questions highlighted above, biophysics will
also doubtless continue to be instrumental.
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